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The acute inflammatory response is a complex defense mechanism that has evolved to respond 
rapidly to injury, infection, and other disruptions in homeostasis. The complex role of 
inflammation in health and disease has made it difficult to understand comprehensively. With the 
advent of high throughput technologies and the growth of systems biology, there has been an 
unprecedented amount of data and –omics analysis aimed at uncovering this complexity. However, 
there still remains a shortage of translational insights for acute inflammatory diseases from these 
studies. In this dissertation, we employ a comprehensive systems approach in order to study the 
coordination of inflammation and identify key control mechanisms, and how these map onto 
clinical outcomes. This process begins with collection of high-dimensional time course data of 
inflammatory mediators, followed by data-driven modeling and network inference that finally 
informs mechanistic computational models for prediction and analysis. In patients with pediatric 
acute liver failure (PALF), we inferred inflammatory networks and identified key differences 
between patients that were survivors versus non-survivors when other analyses proved 
inconclusive. We showed that inflammatory networks can be used both as biomarkers and to 
generate mechanistic hypotheses for this poorly understood disease. In experimental models of 
trauma as well as in human trauma patients, we identify a conserved central network motif of 
cross-regulating chemokines. We develop a logical model based on this hypothesized network, 
which is able to capture both inflammatory trajectory and clinical outcome differences among 
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patients with differing injury severity. These studies suggest that the hypothesized cross-regulatory 
interactions among chemokines MIG, IP-10 and MCP-1 represents an important point of control 
regulating the progression of acute inflammation. We propose that further analysis and validation 
of this hypothesis will require targeted perturbation studies in cells and animals with iterative 
rounds of mechanistic model refinement. We explore an example of such a study focused on the 
anti-inflammatory effects of NAD+, wherein we characterize a signaling pathway that gives rise to 
a complex dose and time dependent induction of TGF-β1.  
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1.0  INTRODUCTION 
  
1.1 INFLAMMATION BACKGROUND 
Inflammation is an essential process in maintaining health and responding to disease. Acute 
inflammation is driven largely by the innate immune system, which not only serves as the first line 
of defense against invading pathogens but also functions to resolve tissue damage and restore 
homeostasis upon a variety of inflammatory conditions including sepsis, trauma, wound-healing, 
and many more. Dysregulated systemic inflammation also plays a significant role in the 
pathophysiology of other diseases that are not primarily attributed to innate immunity, such as 
cancer and diabetes. Although its diseases are varied, the core architecture of the inflammatory 
response to biological stress is highly conserved (1). An infection or tissue injury/damage triggers 
an initially local cascade of events mediated by an array of cells (e.g. macrophages, neutrophils, 
dendritic cells, lymphocytes, etc.) and molecules (cytokines, free radicals, and damage-associated 
molecular pattern molecules [DAMP’s]) that locate invading pathogens or stressed/damaged 
tissue, alert and recruit other cells and molecules, eliminate the offending agents and finally restore 
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the body to equilibrium (2). When dysregulated or over-exuberant, inflammation can be discerned 
in the systemic circulation in the form of altered levels of inflammatory cells and molecular 
mediators. Thus, querying the serum levels of these mediators after an inflammatory stimulus can 
provide information regarding pathophysiology. 
 
Figure 1.1 Complex structure of the innate immune response to biological stress. 
 Following an initiating event (e.g. trauma, hemorrhage, infection), both pro- and anti-inflammatory 
influences (e.g. chemokines, cytokines, lipid products, and free radicals) are elaborated, leading to tissue 
damage or dysfunction. These stressed tissues elaborate DAMPs, which further propagate innate immune 
mechanisms. When the pro-inflammatory mediators exceed defined thresholds, both pro- and anti-
inflammatory mediators spill over into the blood and may cause inflammation to feedback and spread 
systemically to other organs as well. 
 
In sepsis and trauma, this response is concomitant with physiologic manifestations 
including changes in heart rate and body temperature, responses that act in a concerted fashion in 
order to help optimize host defense while minimizing tissue damage. Indeed, although a well 
regulated inflammatory response is essential for proper healing and host defense, an overly 
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exuberant response can become self-perpetuating and lead to organ dysfunction and death (3, 4). 
These vastly different outcomes can be explained by the high-level architecture of the immune 
response, which includes a positive feedback loop from inflammation damage/dysfunction  
inflammation that can drive pathophysiology in inflammatory diseases (Fig 1.1).   
The detrimental effects of self-sustaining inflammation are likely responsible for the 
general perception of inflammation as an inherently harmful process (5, 6). However, in addition 
to the aforementioned beneficial roles of inflammation in the resolution of tissue injury, recent 
studies suggest that morbidity and mortality are worse in animals with low levels of early pro-
inflammatory signals (7). The emerging view of inflammation is indeed more nuanced, casting 
inflammation as a highly coordinated communication network that allows the body to sense and 
respond to challenges and subsequently restore homeostasis(8, 9).  
The current paradigm for acute inflammation, based in large part on studies in response to 
trauma, hemorrhage, or infection, involves a dynamic cascade of cellular and molecular events. 
Innate immune cells such as mast cells, neutrophils, and macrophages are activated directly by 
bacterial endotoxin or indirectly by various stimuli elicited systemically upon trauma and 
hemorrhage (10-13), including the release of cytokines, chemokines, and DAMPs (Fig. 1)(14-16).  
These stimuli enter the systemic circulation and activate circulating monocytes and neutrophils 
(17), which subsequently migrate to compromised tissue by following along a chemoattractant 
gradient induced at the site of injury/infection (18). Activated macrophages and neutrophils 
produce and secrete effectors that activate a variety of immune cells (including further activating 
themselves) as well as non-immune cells such as endothelial cells.  Both DAMPs and pro-
inflammatory cytokines—primary among them tumor necrosis factor-α (TNF-α) (19-25)—
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promote immune cell activation and affect important physiological functions that feedback 
positively to promote further production of inflammatory mediators. This behavior may lead to 
inflammatory tipping points – and concomitant spillover of inflammatory mediators into the blood 
– indicative of cascading system failure that occurs at multiple scales and across multiple 
compartments (26) (Fig. 1.1). In turn, dysregulated inflammation in the blood may itself become 
a driver of further inflammation in other tissues. 
As evidenced by the preceding description, inflammation, like most biological systems, is 
a highly nonlinear system with multiple feedback loops (Fig 1.1). Positive feedback loops allow 
rapid ramping up of a response to biological stress, while the negative feedback works to suppress 
inflammation and restore homeostasis once the threat (infection, damaged tissue, etc.) has been 
eliminated. We suggest that, as has likely occurred in many other complex biological systems (27), 
inflammation has evolved to be robust to a broad range of perturbations but at a cost of fragility in 
key control nodes that may account for the tipping point behavior described above (27) (Fig. 1.1). 
Failure at these points can lead to disease; therefore, characterizing these failure modes, and 
especially the tipping point phenotype, is paramount for the development of effective therapeutic 
interventions (26). Another property of a complex nonlinear system is the ability to exhibit vastly 
different behaviors that depend on initial conditions and parameters (i.e. strengths and rates of 
interactions of components)(28). This heterogeneity, which recapitulates the clinical observation 
of patient-to-patient variability, complicates the prediction of individual patient outcomes using 
the current suite of statistically-based tools (15, 26). Among the possible reasons for this observed 
heterogeneity, one key factor may be that while there are several experimentally well-established 
mechanisms of interactions between inflammatory mediators, many mediators have unknown 
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mechanisms, or differing actions based on context and timing (29). The complex, context-
dependent and individual-specific nature of acute inflammation has made it difficult to modulate.  
To address the aforementioned challenges, we propose to use computational modeling to 
infer networks of interactions among inflammatory mediators directly from data, using an 
approach that can capture the differences and similarities in context and timing of interactions. 
These networks are then correlated with particular clinical outcomes to suggest the role of 
inflammation/inflammatory networks in leading to different outcomes. We gain further insight 
into the functional roles of these networks by constructing mechanistic models of inflammation 
that can be tested and whose properties can be studied in terms of the kinds of behaviors they may 
exhibit. Throughout this process, we seek to infer clinically-relevant features of the inflammatory 
response that were previously inaccessible. As described below, a systems approach to 
inflammation can be useful, indeed necessary, to explain the behavior of the innate immune 
response in individual patients to various biological conditions and ultimately allow for the 
modulation of this response in pathological conditions.  
1.2 COMPUTATIONAL MODELS OF INFLAMMATION 
Systems biology approaches span a broad range of techniques, and can be categorized roughly into 
correlative or causative approaches, with focus on either learning basic principles of system 
organization and function (30-32) or building predictive computational models (30, 33). Although 
there is overlap between these areas, most efforts at elucidating biological mechanisms from high-
dimensional data have traditionally focused on particular points along this spectrum of 
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computational approaches. We suggest that gleaning translationally-relevant insights into the 
inflammatory response and its interconnected (patho)physiology will require the successful 
navigation of this spectrum, in a logical progression from data to models to understanding and 
prediction (26)(Fig 1.2). 
Correlative approaches include regression techniques that build models predictive within 
the conditions of the data they were trained on (34). Although these methods do not provide 
detailed mechanistic insight, these approaches can be used to understand abstract features of the 
response, such as the presence of nonlinearities and the order of the response. The main drawback 
of this class of models is that they are often lack mechanistic insight, and can be over-fit to the 
data on which they were trained. A less-utilized data-driven method is Principal Component 
Analysis (PCA), which reduces a high-dimensional dataset into a few principal components that 
account for much of the observed variance in the data. When applied to time-series data, the 
variables (genes/proteins/etc.) that constitute these principal components may be interpreted as the 
principal drivers of the observed response and can give some mechanistic insights into the 
underlying process (35). In the setting of inflammation, correlative approaches such as PCA may 
facilitate the development of diagnostics by analyzing the cytokine milieu in the blood resulting 
from inflammatory spillover, in order to identify the health state of individuals and possibly inform 
patient-specific interventions (15). While these methods correlate gene/protein levels to phenotype 
and can suggest relevant molecular players involved in a given inflammatory process, these 
methods do not provide much information about how the genes/proteins interact with each other 
(35). 
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In order to better discern organizational aspects of interacting networks of mediators, such 
as co-regulation or auto-induction, a variety of methods have been developed. Hierarchical 
clustering and Bayesian methods use high-throughput genomic or proteomic data of several time-
points and/or conditions to correlate gene expression patterns with function and infer regulatory 
networks of correlated genes. Several developments in these methods over the last two decades 
have yielded more informative networks that can be more easily translated into mechanistic 
models. Among these methods, Dynamic Bayesian Networks (DBNs) are particularly suited for 
inferring directed (causative) networks of interactions based on the probabilistic measure of how 
well the network can explain observed data. DBNs can be supplemented by additional 
experimental evidence and expert knowledge to hypothesize mechanistic models (Fig. 1.2).  
Mechanistic models are derived from more detailed biological and physical descriptions of 
a system have a rich set of tools for both analysis and simulation. These models, based on causative 
interactions, can be constructed as ordinary differential equations (ODEs), rules-based models 
(RBMs), and agent-based models (ABMs) among other methods (including hybrid methods), and 
have the advantage of potentially being predictive outside the range of conditions/time-points that 
they were calibrated on. Although it is often difficult to parameterize such models, they can unveil 
emergent phenomena that not immediately obvious from the interactions that are encoded in the 
model.  
There are several analytic tools, especially for ODE models, that have been developed and 
used to uncover the organizational principles of networks (or sub-networks), the properties that 
explain the dynamics and robustness/sensitivity of a given complex system, and, perhaps most 
importantly, the critical points of control in the system (32). These tools are particularly important 
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in order to help define the complex interplay between the inflammatory mediators in the blood and 
tissues. Tools from dynamical systems theory allow identification of the possible steady state(s) 
of a system as well as the kinetics of the system’s time evolution. These tools have been used 
extensively to explain (or predict, depending on the context) diverse behaviors such as bistability, 
hysteresis, and oscillations in a variety of biological systems (36). Bifurcation diagrams, in 
particular, can be used to map out the effects of a particular parameter on the possible steady state 
behaviors of a system, and to indicate the transition from a healthy steady state to a pathological 
one(37-39). The relative importance of parameters can also be quantified by calculating the change 
in the model output in response to changes in the parameter values using sensitivity analysis (32, 
40). These methods work in a complementary fashion to identify the key points that can be 
modulated to change the behavior of a system (Fig. 1.2). 
 While we wish to navigate through process of data to data-driven model to mechanistic 
model to prediction and understanding of the innate immune response, we seek to put it in the 
perspective of translational applications with a focus on clinical and pre-clinical settings. Much of 
the work in systems biology has understandably been in simpler, well-studied model organisms, 
but even among studies focused on pre-clinical science, there has been an overall lack of translation 
to the clinical arena.  The studies in this dissertation follow the framework of Translational 
Systems Biology, which focuses on translational insights for novel diagnostic or therapeutic 
purposes and predictive mathematical models that can inform in silico clinical trials (41, 42).  
  8 
  
Figure 1.2 Overview of workflow for integrating data-driven and mechanistic modeling. 
Multiplexed timecourse data is measured and causal interactions are inferred by Dynamic Bayesian 
Networks. Inferred network topology forms the basis of mechanistic equation-based models that can be 
simulated to compare to experimental/clinical data, suggest diagnostic initial conditions, and analyzed and 
validated with further experiments. Along the path, we generate more focused hypotheses, from associating 
dynamic patterns of inflammatory mediators with phenotype, to hypothesizing functional roles for particular 
interactions in the inflammatory network.  
1.3 OVERVIEW AND CONTRIBUTIONS 
As outlined in the preceding sections, an integrated computational and experimental 
approach may prove essential in deciphering the complexity of the acute inflammatory response. 
Current technology allows the simultaneous measurement of a multitude of inflammatory 
parameters including cells, (molecular) inflammatory mediators, and physiologic parameters. The 
  9 
challenge lies in obtaining mechanistic insight from often highly variable, multidimensional data. 
In this dissertation, we address this challenge by following the workflow outlined in Figure 1.2. 
We first measure multiple inflammatory mediators across time in order to query the dynamics of 
the overall innate immune response. A key feature of our data is measurement at multiple time 
points early in the response to an insult (e.g. within first 24 hours after traumatic injury). We 
hypothesize that the control points that dictate final system behavior operate within this critical 
period. Indeed, we see that the greatest variations in concentrations of inflammatory mediators 
occur within this period, indicating that it contains the richest dynamics. 
 In chapter 2, we use the aforementioned time course data to first infer causal relationships 
among inflammatory mediators using Dynamic Bayesian Networks (DBNs, step 2 in Figure 1.2). 
To account for the nonlinear and time-dependent nature of inflammatory mediator interaction, we 
use a non-linear generalization of standard DBNs, as described by Grzegorczyk & Husmeier (43). 
The parameters indicating strengths of interaction are integrated out in their algorithm in order to 
efficiently learn a nonlinear DBN. We develop a method of estimating these parameters post hoc 
using linear regression, after the network inference. Thus we provide a valuable tool to quickly 
and agnostically learn whether interactions are stimulatory or inhibitory, which is essential 
information for biological processes. We apply the aforementioned network inference algorithm 
to infer differential networks of inflammation in Pediatric Acute Liver Failure patients that were 
grouped according to survival outcomes in section 2.3. Network inference proved invaluable, as 
other statistical techniques were unable to differentiate the inflammatory response among 
spontaneous survivors, liver transplant recipient survivors, and non-survivors. In Section 2.4, we 
analyze inflammatory networks in Trauma and Hemorrhagic Shock (T/HS), comparing results 
from a mouse model with those from human trauma patients. We observe key differences between 
 10 
the case of trauma with and without hemorrhagic shock that suggest mechanistic differences in the 
progression of inflammation in these settings. After accumulating results from various settings 
spanning cell, animal, and human acute inflammation, we hypothesize a conserved network 
module comprising of cross-regulating chemokines, which we term “chemokine switching motif”, 
and hypothesize that this may drive differential inflammatory trajectories.  
While network inference can help hypothesize important interactions in the inflammatory 
response, we sought to further investigate the functional principles and behaviors that are 
associated with these networks by constructing mechanistic equation based models in Chapter 3. 
In Section 3.1, we develop a logical model based on the conserved chemokine network motif 
observed in the DBNs. The model was calibrated to capture the differences in mean inflammatory 
trajectory for populations of patients who were injured with moderate or severe injury. Although 
the model was fit to mean data, it was able to capture differences in the trajectories of 
subpopulations of patients. We map out the dynamical behavior of the model for all possible 
starting conditions and find that differences in the time for the model to reach steady state between 
moderate and severe injury simulations match closely with clinically observed patient discharge - 
a novel way to link modeling results to relevant clinically observed phenomena. Taken together, 
these studies suggest that the inferred chemokine switching motif comprising of MIG, IP-10 and 
MCP-1 may represent a control strategy that regulates the progression of acute inflammation. 
Further analysis and validation of this hypothesis will require targeted perturbation studies in cells 
and animals with iterative rounds of mechanistic model refinement. In section 3.2, we describe 
such a study wherein we characterize a signaling pathway that gives rise to a complex dose and 
time dependent induction of TGF-β1 by NAD+, a potent anti-inflammatory mediator. To 
summarize, the major contributions of this dissertation are: 
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• Establishing a protocol for gaining mechanistic insight from multidimensional 
data through a rational progression from data-driven to mechanistic modeling 
(Figure 1.2) 
• Establishing network inference as a tool to generate quasi-mechanistic hypotheses 
regarding differences in inflammation between disease phenotypes/clinical 
outcomes  
• Estimating the parameters of the DBNs inferred from Grzegorczyk & Husmeier’s   
method post hoc using multiple linear regression 
• Showing that patients suffering from Pediatric Acute Liver Failure have distinct 
networks of inflammation associated with survival, non-survival, and liver 
transplantation 
• Showing that inflammatory networks in human trauma are driven primarily by 
chemokines MIG and MCP-1, with a greater role for MCP-1 in patients that also 
have hemorrhage. Showing analogous results for a mouse model of 
trauma/hemorrhage for the chemokines IP-10 and MIG.  
• Developing a logical model of the inferred chemokine switching motif and 
showing that this model can capture differences in the inflammatory dynamics of 
subpopulations of trauma patients and map model behavior onto patient discharge 
• Identifying the signaling pathway that leads to the complex induction of TGF-β1 
by NAD+ by combined computational modeling and experiments 
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2.0  NETWORKS OF INFLAMMATORY MEDIATORS IN ACUTE 
INFLAMMATION 
Many data-driven methods help to identify which mediators are central for a particular 
process and can help discriminate between groups. Previous studies of inflammatory mediators in 
Trauma/Hemorrhagic Shock (T/HS) have identified such mediators (44). Network inference can 
suggest how these inflammatory mediators may interact, providing us with another dimension to 
compare groups and generate hypotheses, and giving insight into the architecture of the 
inflammatory response. Indeed, when other statistical test and data-driven methods were unable to 
adequately distinguish survivors from non-survivors in transplant recipients of patients with 
Pediatric Acute Liver Failure (PALF), DBNs inferred for each group showed clear differences in 
their inflammatory networks (45) (Section 2.3). Based on our preliminary results, we have 
hypothesized a potential core structure of interaction among inflammatory mediators that may play 
a role in determining the trajectory of the innate immune response, and whether it leads to a 
healthy, self-resolving state or an over-exuberant and self-maintaining elevated pro-inflammatory 
state. We have demonstrated that we can infer dynamic networks of inflammatory mediators in 
T/HS. 
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2.1 BACKGROUND 
Network inference in biology has been an intense area of study since the advent of high throughput 
biological data. Biological processes are characterized by the interaction among biomolecules. 
These interactions can be studied either by direct measurement of binding, observing phenotypic 
changes by targeted perturbations, large scale changes in expression after perturbations, or by 
analyzing the time courses of the various genes/proteins. The last two are particularly powerful as 
they consider the systemic level rather than a reductionist approach. Although network inference 
methods were originally used to learn gene regulatory pathways from microarray data, 
advancements over the last decade have facilitated their use in investigating proteomic 
interactions, signaling pathways, and integrating heterogeneous biological data (46). Bayesian 
methods in particular have been useful for the latter, as they frame the problem in a probabilistic 
context and allow integration of diverse datasets. However, the majority of studies on 
inflammation measure the transcriptional response at a genome-wide level to correlate sets of 
genes with different phenotypes (47-49), including those focused on cytokines (50). Proteomic 
studies have been limited to correlative approaches or focused on cytokine signaling within single 
cells (51, 52). Inflammatory mediators function primarily to the recruit and/or activate cells to 
change both their expression and secretion profiles. Therefore, we hypothesize that measuring 
protein concentrations at the bulk (tissue/blood) level as opposed to gene expression or signaling 
within single cells is more relevant in discerning the interaction among these mediators across 
cells. We choose to measure inflammatory mediators in the blood because it is an easily accessible 
compartment for obtaining serial samples, especially in human patients. Unlike the aforementioned 
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studies, this allows us to capture the coordination of the response across multiple tissues and cell 
types. These interactions are not necessarily direct protein-protein or gene-gene interactions, but 
they provide an idea of how inflammatory mediators eventually influence each other at the protein 
level, which is generally their functionally active form (in the context of inflammatory trajectories)  
Dynamic Bayesian Networks (DBNs) are particularly suited for inferring directed 
networks of interactions. By allowing edges (interactions) from nodes in one time point towards 
nodes in the following time point, DBNs can represent feedback loops, which are lacking in 
standard Bayesian networks. The general method to learn DBNs involves iterating through the 
process of i) proposing a candidate graph (network) structure, ii) given the graph and experimental 
data, finding the best conditional probabilities for each node, and iii) scoring the candidate network 
based on i) and ii). To discuss the method in more detail, we follow the approach from Markowetz 
& Spang’s review (46), beginning with the simplest case that utilizes statistical correlations 
between variables to infer connections, and then introduce graphical modeling methods that 
account for the possible influence of other variables when inferring connections between two given 
variables.  
2.1.1 Coexpression Networks and Conditional Independence 
A simple way of inferring that two genes/proteins interact or are functionally related is to use the 
guilt-by-association principle. That is, if the similarity of their expression profiles is above a 
threshold, they are considered to be connected. Similarity can be measured by common statistical 
tests, such as Pearson’s correlation, or by more sophisticated non-linear similarity measures like 
mutual information or non-linear kernel functions (46). However, although 0 correlation 
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corresponds to statistical independence, high correlation is still a weak criterion for statistical 
dependence. High correlation may occur by chance, depending on the size of the data.  Moreover, 
correlation cannot distinguish between direct and indirect dependences, as it is measured by 
pairwise tests that do not account for the possible influence of other variables in the network. One 
way to resolve this uncertainty is to use the concept of conditional independence.  
If X, Y, and Z are random variables then X is conditionally independent of Y given Z if 
and only if  
𝑃𝑃(𝑋𝑋 = 𝑥𝑥,𝑌𝑌 = 𝑦𝑦 | 𝑍𝑍 = 𝑧𝑧) = 𝑃𝑃(𝑋𝑋 = 𝑥𝑥 | 𝑍𝑍 = 𝑧𝑧)𝑃𝑃(𝑌𝑌 = 𝑦𝑦 | 𝑍𝑍 = 𝑧𝑧) 
Or equivalently, (𝑋𝑋 = 𝑥𝑥 | 𝑌𝑌 = 𝑦𝑦,𝑍𝑍 = 𝑧𝑧) = 𝑃𝑃(𝑋𝑋 = 𝑥𝑥 | 𝑍𝑍 = 𝑧𝑧) 
In other words, given that we know the value of Z, knowing the value of Y gives no new 
information and is irrelevant for explaining the value of X. Conversely, any correlation between 
X and Y can be fully explained by the variable Z. Thus, considering conditional independence 
allows us to differentiate between direct and indirect relationships by asking whether the 
correlation between two variables can be explained by a third variable (or set of variables). A 
powerful way to encode and manage conditional independencies is to use graphical models.  
2.1.2 Graphical Models 
In probabilistic graphical models(53-55), variables are represented as nodes and their relationships 
are represented by directed edges. They provide a compact representation of the joint probability 
distribution (JPD) of a set of variables by utilizing conditional independencies to factorize the JPD. 
Graphical models may be undirected (i.e. Markov Random Fields) or directed (i.e. Bayesian 
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Networks). Undirected graphical models consider whether the correlation between two variables 
can be explained by all other variables in the network. In other words, Z from the preceding 
discussion now represents the set of all other variables. In the Gaussian setting, assuming that the 
covariance matrix ∑ is invertible, we can define K = ∑-1 as the precision matrix, and the value 
−𝑘𝑘𝑖𝑖𝑖𝑖/�𝑘𝑘𝑖𝑖𝑖𝑖𝑘𝑘𝑖𝑖𝑖𝑖 as the partial correlation coefficient between variables i and j. Then, kij = 0 means 
that variables i and j are conditionally independent given the rest of the variables. Thus, a Gaussian 
Graphical Model (GGM) can be defined whose edges are defined by non-zero partial correlation 
coefficients(55). This graph represents the correlation between variables after accounting for all 
other variables in the model. However, these models suffer from insufficient data for inference, as 
the number of observations/samples has to be much larger than the number of variables, which is 
rarely the case for biological data. Moreover, they do only consider the set of all other variables 
when calculating conditional independence, although there may be only specific subsets that lead 
to conditional independence between genes.  
Directed graphical models consider whether two variables are conditionally independent 
given all possible subsets of other variables. An added benefit of directed graphical models is that 
the regulatory relationships among the variables are clear to see in the graphical representation. 
Specifically, an edge from X to Y in the graph means that Y is conditionally independent of its 
non-descendants, given X. In other words, the probability distribution of node Y can be specified 
by knowing the value of its parent node X, regardless of the values of other nodes in the graph. 
This dependency relationship can be loosely interpreted as X “causes” Y. This a stronger criterion 
for inferring causality than correlative methods, as in addition to specifying direction, an edge in 
a Bayesian Network (BN) means that no other subset of variables can explain the correlation 
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between the parent and child nodes (46). It is important to note however that, in order for efficient 
inference, the structure of the graph must be acyclical (53, 56).  
2.1.3 Bayesian Networks 
To fully define a BN, we need to specify both a graph structure and corresponding parameters for 
the conditional probabilities. In the simplest, discrete variable case, the probability distributions 
are presented in conditional probability tables. For each state of the parent variable, the probability 
of the child variable being in one of its possible states can be calculated by observing the frequency 
of its occurrence in a training data set. In the case of biological data, which is often composed of 
continuous-valued concentration or expression levels, it is more appropriate to use continuous 
variables. Instead of tables, conditional probability densities, such as Gaussian distributions, are 
used to model the relationship between connected nodes(54, 56). For instance, Y is normally 
distributed with a particular mean and variance when X=x, i.e. P(Y|X) ~ N( B0 + B1(X=x), σ2). 
Similar to the discrete case, the parameters (the mean and variance of the Gaussian) would be 
estimated from a training dataset. In Gaussian Bayesian Networks, the distribution of each variable 
is a Gaussian distribution with a mean and variance defined by a linear combination of the parent 
variables.  
There are two classes of algorithms for learning the structure of BNs: constraint-based 
algorithms and score-based algorithms(54, 55). Constraint-based algorithms, which require the 
testing of conditional dependence between node pairs, given every possible subset of other nodes, 
are generally computationally infeasible for the number of variables modeled in biological studies 
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(46). Score-based methods avoid this problem by posing the structure learning task as an 
optimization problem. A scoring metric is first defined for evaluating how well a particular model 
(structure) fits to the data. The goal then is to find the maximum-scoring structure(s) by searching 
through the discrete space of possible structures. The simplest scoring metric is the Maximum 
Likelihood estimate – however, this score suffers from overfitting as it increases with the number 
of parameters and edges in a graph. Regularization parameters may be added to ML scores, but 
the full Bayesian approach is preferred because of its built-in regularization. This score is defined 
by the posterior probability of observing the model structure, G, given the data, D: 
𝑃𝑃(𝐺𝐺|𝐷𝐷) = 𝑃𝑃(𝐷𝐷|𝐺𝐺)𝑃𝑃(𝐺𝐺)
𝑃𝑃(𝐷𝐷)  
The denominator is the same for all models and thus does not need to be computed when 
comparing model scores. The key component of Bayesian scoring metrics is the marginal 
likelihood, which is averaged over parameters of local probability distributions i.e. the parameters 
are integrated out.  
𝑃𝑃(𝐷𝐷|𝐺𝐺) = � 𝑃𝑃(𝐷𝐷|𝐺𝐺, 𝜃𝜃)𝑃𝑃(𝜃𝜃|𝐺𝐺)𝑑𝑑𝜃𝜃
𝜃𝜃
 
The marginal likelihood can be computed analytically, depending on the choice of local probability 
distributions and corresponding conjugate priors. Structure priors, P(G), may be chosen to 
incorporate prior biological knowledge or focus on specific types of interactions.  
 The space of all possible graph structures is super-exponential in the number of nodes, 
therefore we must use some heuristics to search through this space. One class of heuristics is based 
on Markov Chain Monte Carlo. In this method, we start with some network and make a local 
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perturbation (i.e. add/delete/invert one edge) and accept the new structure with some acceptance 
criterion (such as the Metropolis-Hastings acceptance criterion).  
2.1.4 Dynamic Bayesian Networks 
A major restriction of Bayesian Networks is that cyclical loops in the graph are not allowed. 
However, feedback is an essential feature of biological networks and therefore important to model 
when inferring networks of interactions among biological agents. Dynamic Bayesian Networks 
(DBNs) allow for inference of feedback by indexing the variables by discrete timepoints, in effect 
unrolling the network in time (Figure 2.1)(57).  Generally, each time slice contains an instance of 
the variables being modeled (X1…Xn) and edges are drawn from parent nodes at time t to the nodes 
they influence at time t+1. More generalized cases that allow edges within a time slice or between 
time slices of distance greater than 1 may also be constructed.  
 
 
Figure 2.1 Dynamic Bayesian Network. 
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2.2 NETWORK INFERENCE METHODOLOGY 
2.2.1 Grzegorcyk & Husmeier’s changepoint BGe DBN algorithm 
We use the Matlab code provided by Grzegorczyk et al for their algorithm, described in detail in 
(43). Briefly, we have a set of variables (nodes) that represent the different inflammatory mediators 
in our model, X1,…XN and a directed graph (network) structure G that describes the interactions 
between them. The parent set of each node Xn, denoted by 𝜋𝜋𝑛𝑛(𝐺𝐺), is the set of nodes that influences 
the value of node Xn. Intra-timepoint interactions are not considered, as parent node sets for Xn 
are only considered from X1,t-1,…XN,t-1. The model proposed by Grzegorczyk et al is a non-
stationary generalization of the Bayesian Gaussian with score equivalence (BGe) model (58) and 
is essentially a node-specific mixture of BGe models. The marginal likelihood is given by: 
𝑃𝑃(𝐷𝐷|𝐺𝐺,𝑽𝑽,𝑲𝑲,𝜽𝜽) = ���𝜓𝜓�𝐷𝐷𝑛𝑛𝜋𝜋𝑛𝑛�𝑡𝑡,𝜽𝜽𝒏𝒏𝒌𝒌��𝛿𝛿𝑽𝑽𝑛𝑛(𝑡𝑡),𝑘𝑘κ𝑛𝑛
𝑘𝑘=1
𝑚𝑚
𝑡𝑡=2
𝑁𝑁
𝑛𝑛=1
 
 
𝜓𝜓�𝐷𝐷𝑛𝑛
𝜋𝜋𝑛𝑛�𝑡𝑡,𝜽𝜽𝒏𝒏𝒌𝒌��𝛿𝛿𝑽𝑽𝑛𝑛(𝑡𝑡),𝑘𝑘 = 𝑃𝑃�𝑋𝑋𝑛𝑛(𝑡𝑡) =  𝐷𝐷𝑛𝑛,𝑡𝑡|𝜋𝜋𝑛𝑛(𝑡𝑡 − 1) = 𝐷𝐷(𝜋𝜋𝑛𝑛,𝑡𝑡−1),𝜽𝜽𝒏𝒏𝒌𝒌�  (1) 
 
Where D is the time course data, 𝛿𝛿𝑽𝑽𝑛𝑛(𝑡𝑡),𝑘𝑘 is the Kronecker delta, V is a matrix of latent variables 
that indicate which mixture component a data point has been generated by, and K = (κ1,…κn) is 
the vector of mixture components (see (43) and corresponding supplementary information for 
more details). The data points are assigned to mixture components by a discrete changepoint 
process. The vector Vn thus divides the data for each node into different time segments (between 
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changepoints), each pertaining to a separate BGe model with parameters 𝜃𝜃𝑛𝑛𝑘𝑘, resulting in a model 
with non-stationary parameters. This allocation scheme provides the approximation of a nonlinear 
regulation process by a piecewise linear process. The marginal likelihood conditioned on the latent 
variables is then given by 
 
           𝑃𝑃(𝐷𝐷|𝐺𝐺,𝑽𝑽,𝑲𝑲) = �𝑃𝑃(𝐷𝐷|𝐺𝐺,𝑽𝑽,𝑲𝑲,𝜽𝜽)𝑃𝑃(𝜽𝜽)𝑑𝑑𝜽𝜽 = �Ѱ∗�𝐷𝐷𝑛𝑛𝜋𝜋𝑛𝑛[κ𝑛𝑛,𝑽𝑽𝒏𝒏]� 𝑁𝑁
𝑛𝑛=1
                          (2) 
                                    Ѱ∗�𝐷𝐷𝑛𝑛𝜋𝜋𝑛𝑛[κ𝑛𝑛,𝑽𝑽𝒏𝒏]� = �Ѱ�𝐷𝐷𝑛𝑛𝜋𝜋𝑛𝑛[𝑘𝑘,𝑽𝑽𝒏𝒏]�                                               (3) κ𝑛𝑛
𝑘𝑘=1
 
  Ѱ�𝐷𝐷𝑛𝑛𝜋𝜋𝑛𝑛[𝑘𝑘𝑛𝑛,𝑽𝑽𝒏𝒏]� = ��  𝑚𝑚
𝑡𝑡=2
𝑃𝑃�𝑋𝑋𝑛𝑛(𝑡𝑡) =  𝐷𝐷𝑛𝑛,𝑡𝑡|𝜋𝜋𝑛𝑛(𝑡𝑡 − 1) = 𝐷𝐷(𝜋𝜋𝑛𝑛,𝑡𝑡−1),𝜽𝜽𝒏𝒏𝒌𝒌� 𝑃𝑃�𝜽𝜽𝒏𝒏𝒌𝒌|𝜋𝜋𝑛𝑛�𝑑𝑑𝜽𝜽 
 
Equation 3 is the local changepoint BGe (cpBGe) score for node Xn, and has a closed-form solution 
(43). Changepoints are sampled from a point process prior using dynamic programming, and 
graphs are sampled by sampling parent node sets (restricted to a maximum of three parents per 
node) for each node directly from a Boltzmann posterior distribution based on the cpBGe score. 
The marginal edge posterior probabilities can be estimated simply by computing the frequency of 
existence of an edge from node xi to node xj in the sampled networks and dividing by the number 
of samples. For our studies, graphs are inferred in one of two ways: 1) using a single time course 
of the mean values for each variable and 2) individually for each sample (e.g. each patient), and 
the marginal edge probabilities are averaged to give a final consensus graph structure for the group. 
We include only edges (interactions) that have an averaged edge probability > 0.5 in the consensus 
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network, although this threshold can be adjusted to give sparser or denser networks. The authors 
measure the performance of this algorithm on synthetic computationally simulated data (i.e. data 
generated from a deterministic model with Gaussian noise) as well as synthetic biological data 
(expression levels from a synthetic gene circuit in yeast) and show that it outperforms TSNI (59) 
and Banjo (60), two popular network inference methods.  
2.2.1.1 Computing Influence Scores for Directed Edges 
The output of the aforementioned algorithm is a final graph structure indicating the interactions, 
as well as the node-specific changepoint set indicating time segments across which the interaction 
parameters vary. Because interactions within a particular time segment are modeled as linear 
combinations of parent nodes, we will compute the coefficients of influence of each parent node 
on a child node by multiple linear regression within that time segment. The overall influence score 
will be computed by determining the duration of positive or negative coefficient time segments. 
That is, the score for edge from node x to node y is given by  
𝑆𝑆𝑥𝑥,𝑦𝑦 = �𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝛽𝛽𝑐𝑐) ∗𝐶𝐶
𝑐𝑐=2
(𝑡𝑡𝑐𝑐 − 𝑡𝑡𝑐𝑐−1) 
Where βc is the coefficient of linear regression of y on x (multiple linear regression if y has multiple 
parents), C is the total number of changepoints, and tc is the time corresponding to the cth 
changepoint. As a test case, we generated simulated data with Gaussian noise to see if we could 
correctly infer the interactions as well as the label of positive or negative. Data were generated 
according to the following equations: 
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𝑋𝑋1(𝑡𝑡) = � 1 + 𝜀𝜀, 2 ≤ 𝑡𝑡 ≤ 10 −1 + 𝜀𝜀, 11 ≤ 𝑡𝑡 ≤ 20 
𝑋𝑋2(𝑡𝑡) = �−3𝑋𝑋1(𝑡𝑡 − 1) + 0.3 ∗ 𝜀𝜀, 2 ≤ 𝑡𝑡 ≤ 10 −𝑋𝑋1(𝑡𝑡 − 1) + 0.3 ∗ 𝜀𝜀, 11 ≤ 𝑡𝑡 ≤ 20 
𝑋𝑋2(𝑡𝑡) = � 2𝑋𝑋1(𝑡𝑡 − 1) + 0.3 ∗ 𝜀𝜀, 2 ≤ 𝑡𝑡 ≤ 6 −2𝑋𝑋1(𝑡𝑡 − 1) + 0.3 ∗ 𝜀𝜀, 7 ≤ 𝑡𝑡 ≤ 152𝑋𝑋1(𝑡𝑡 − 1) + 0.3 ∗ 𝜀𝜀, 16 ≤ 𝑡𝑡 ≤ 20 
Where 𝜀𝜀 is a random number drawn from the standard normal distribution. The value at the first 
time point for each variable is also drawn from a standard normal. In this case, we have a common 
changepoint for X1 and X2 at t =10, whereas X2 has two changepoints at t=6 and t=15. The output 
of the DBN inference algorithm is depicted in Figure 2.2. 
 
 
Figure 2.2 A Co-allocation matrices for each variable showing posterior probability of two time points 
being assigned to same mixture component.  B. Final graph structure inferred for simulated data with 
inferred correlation coefficient for each time segment.  
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Figure 2.2A depicts the co-allocation matrices for each variable, showing the marginal 
posterior probability of two time points being assigned to the same mixture component from 0 
(black) to 1 (white). The boundaries of white boxes indicate the location of changepoints, with 
time segments between changepoints. The final graph structure is color coded with red-yellow-
green color scheme depending on whether the influence score is positive, neutral or negative 
(Figure 2.2B). The edges are also labeled with the correlation coefficient and R2 for each time 
segment. The information about influence scores and segmentations will be used to guide future 
studies. For the studies in this thesis, we report only the final graph structure.   
2.3 UNIQUE DYNAMIC NETWORKS ASSOCIATED WITH DEATH AND 
SPONTANEOUS SURVIVAL IN PEDIATRIC ACUTE LIVER FAILURE 
This section is edited from a paper published in PLoS ONE (45). In this work, Dynamic Bayesian 
Networks are used to infer inflammatory networks for patients with pediatric acute liver failure 
(PALF). Although raw inflammatory mediators assessed over time could not distinguish among 
patient outcomes, DBN analysis revealed distinct interferon-gamma-related networks that 
distinguished spontaneous survivors (SS) from those who died (NS). The network identified in 
liver transplant recipients (LTx) pre-transplant was more like that seen in spontaneous survivors 
than in those who died, a finding supported by PCA. My role in this study was to implement and 
interpret the network analysis of inflammatory mediator profiles in PALF patients.  
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2.3.1 Introduction 
Pediatric acute liver failure (PALF) is a complex, catastrophic, rapidly evolving clinical 
syndrome (61).  Like all complex diseases, the clinical trajectory of PALF is dynamic and non-
linear.  Its course reflects a complex  interaction among the child’s clinical condition,  response to 
supportive care, disease severity, potential for recovery, and availability of a suitable organ if liver 
transplantation (LTx)  is believed to be life-saving (62).  Yet, LTx is irreversible and impacts both 
society, in terms of organ allocation, as well as the individual patient and family coping with life-
long immunosuppression and monitoring.  Identification of patients likely to survive or die or 
whose condition would not benefit from LTx is necessary to inform LTx decisions.   
Outcomes in PALF vary both between and among diagnostic categories, yet LTx occurs 
more commonly among those patients with an indeterminate diagnosis (63) .  Recent data suggest 
immune or inflammatory dysregulation occurs in the setting of acute liver failure (ALF).  For 
example, patients with acute liver failure (ALF) have increased risk for bacterial and fungal 
infections (64), aplastic anemia (65, 66), and impaired cell-mediated and humoral immunity (64). 
Moreover, evidence of immune-inflammatory activation, characterized by marked elevation of 
soluble interleukin-2 receptor alpha (sIL-2R α), was identified in PALF (67).  These observations 
led us to hypothesize that immune or inflammatory dysregulation is present in PALF. 
Acute inflammation elicits interrelated immune, inflammatory, neuronal, and 
physiological responses that can lead to severe organ dysfunction and death (2). The complexity 
of the inflammatory response has stymied attempts at therapeutic modulation of acute 
inflammation. Computational modeling of complex systems is emerging as an approach to address 
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the plethora of known and unknown interactions among biologic pathways (32), including those 
pathways operant in inflammation (9). Recently, we used computational algorithms to assess 
multiple circulating inflammatory mediators coupled to dynamic network analyses to suggest both 
drivers and markers of inflammation in the setting of experimental trauma/hemorrhage in mice 
(44). This methodology allowed us to identify unique cytokine interactions between mice 
undergoing trauma/hemorrhage compared to those who underwent sham intravenous cannulation 
procedure alone (44).   
Our goal in the present study was to apply a similar methodology to PALF.  Identification 
of immune/inflammatory networks will likely reflect dynamic changes in the inflammatory 
response and could lead to opportunities for directed therapeutic intervention, enhance liver 
transplant decisions, and improve patient outcomes.   
2.3.2 Methods 
2.3.2.1 PALF participants 
This was a cohort study conducted through the Pediatric Acute Liver Failure Consortia (PALF; 
National Institutes of Health/National Institutes of Diabetes, Digestive, and Kidney Disease: 5U01 
DK072146).   Patients less than 18 years of age were eligible for enrollment into the PALF registry 
if they met the following entry criteria: 1) no known evidence of chronic liver disease, 2) 
biochemical evidence of acute liver injury, and 3) hepatic-based coagulopathy (not corrected with 
vitamin K) defined as a prothrombin time (PT) ≥ 15 seconds or international normalized ratio 
(INR) ≥ 1.5 in the presence of clinical hepatic encephalopathy (HE), or a PT ≥ 20 seconds or INR 
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≥ 2.0 regardless of the presence or absence of HE. During the period of this study, the PALF study 
group consisted of 22 pediatric sites: 19 centers in the United States, one in Canada, and two in 
the United Kingdom. Patient enrollment began in December 1999.  The study was approved by 
the Institutional Review Boards from all of the participating institutions, and the NIH provided a 
Certificate of Confidentiality to the study. Written informed consent was obtained from the parents 
or guardians of the children in the study.   
After enrollment into the PALF cohort, demographic and clinical data were recorded daily 
for up to seven days. Diagnostic evaluation and medical management were under the direction of 
the attending physician at each participating institution, and were consistent with the standard of 
care at each site.  A final diagnosis for the cause of PALF was assigned by the primary physician 
at each study site as summarized previously (61).  21-day outcomes were recorded as death without 
transplantation, LTx, or survival without LTx.  A single daily serum sample was scheduled to be 
collected with the first morning blood draw following enrollment and daily for up to seven days, 
or until death, LTx, or discharge from hospital.  The serum sample was divided into 250 µL or 500 
µL aliquots, promptly frozen at -80ºC at the enrollment site and later batch-shipped to the research 
bio-repository long-term storage.  The frequency and volume of serum that could be collected for 
research purposes was dependent upon patient weight, hemoglobin, and the daily volume of blood 
required for diagnosis and patient management.  Given these patient safety restrictions, research 
samples were not available at all potential time points for all PALF cohort participants.    
A study cohort for this analysis was selected from the PALF cohort.  We identified a 
convenience sample of participants to serve as the study cohort.  Participants in the study cohort 
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were to have at least 3 daily samples with at least 100 µL of serum.  From those participants, the 
study cohort was further prioritized to capture those with the most samples available between study 
entry and outcome, and to recapitulate the diversity of age, diagnosis and outcome throughout the 
PALFSG as a whole.   
2.3.2.2 Assays of inflammatory mediators 
We chose chemokines, cytokines, and reactive nitrogen oxide species that serve generally or 
specifically as biomarkers for various phases of the  complex inflammatory response. Cytokines 
and chemokines (eotaxin, granulocyte-macrophage colony stimulating factor [GM-CSF], 
interferon [IFN]-α2, IFN-γ, interleukin [IL]-1β, IL-1 receptor antagonist [IL-1ra], IL-2, soluble 
IL-2 receptor α chain [sIL-2rα], IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40, IL-12p70, IL-13, 
IL-15, IL-17, IFN-γ-inducible protein of 10 kDa [IP-10; CXCL10], monocyte chemotactic protein-
1 [MCP-1; CCL2], monokine induced by γ-interferon [MIG; CXCL9], macrophage inflammatory 
protein [MIP]-1α, MIP-1β, and tumor necrosis factor [TNF]-α) were assayed using a Luminex™ 
100 IS apparatus (Luminex™, Austin, TX) using specific beadsets (Millipore, Billerica, MA). The 
nitric oxide reaction products NO2- + NO3- were assayed using the nitrate reductase method 
(Cayman Chemical, Ann Arbor, MI).   
2.3.2.3 Statistical analyses 
Patients’ gender and coma grade at enrollment are reported as percentages. Outcomes are reported 
at 21 days. Age at enrollment is reported as medians (25th and 75th percentiles).  Pearson chi-square 
tests were used to test differences in proportions between those patients in this inflammatory study 
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and those not in this study, but in the PALF registry cohort.  Wilcoxon Rank-sums tests were used 
to test for differences in distributions of age between the two groups.  P-values less than 0.05 were 
used to determine statistical significance.   
2.3.2.4 Patient-Specific Principal Component Analysis (PCA) 
Principal Component Analysis is a statistical method to reduce the dimensionality of data by 
finding new axes, or components, along which the variables exhibit the greatest variance or 
response (68, 69).  This analysis identified subsets of mediators that most strongly correlated with 
the inflammatory response trajectory of an individual patient using at least 3 samples for each 
patient.  A PCA score was then calculated for each cytokine, summarizing the relative degree to 
which that cytokine contributed to the inflammatory response for that patient over time.  The PCA 
scores were used to group participants using hierarchical clustering as described below. Resultant 
patient sub-groups were then cross-correlated with clinical outcomes: spontaneous survivor (SS), 
non-survivor with native liver (NS), or received LTx (LTx). This method was unbiased in that all 
the patients’ data were subjected to PCA independent of outcome groups. 
2.3.2.5 Hierarchical clustering analysis 
This analysis highlighted the natural variability, as well as any overlap, in inflammatory mediators 
from among SS, NS, and LTx PALF participants. The details of this analysis are provided in the 
Appendix A.2. The calculation is performed by using the Bioinformatics Toolbox in Matlab® 
7.6.0, and the code for this algorithm and an explanation of its use in the context of experimental 
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trauma/hemorrhagic shock has been made available publicly (44). This method is unbiased, and 
so the segregation of post-PCA data by hierarchical clustering was likewise unbiased. 
2.3.2.6 Dynamic Bayesian Network Analysis 
 This analysis delineated the connectivity among circulating inflammatory mediators as a function 
of time, thereby describing a possible biomarker signature as well suggesting possible mechanisms 
by which the progression of the inflammatory response differs based on patient sub-group. In this 
analysis, time courses of unprocessed cytokine measurements (e.g., measurements were not 
converted to PCA or to fold change over baseline, or normalized in any other way) from each 
experiment were used as input for a Dynamic Bayesian Network (DBN) inference algorithm, 
implemented in Matlab® as described in Section 2.2 (43).  
2.3.3 Results 
2.3.3.1 PALF participants 
There were 986 participants enrolled in PALF at the time of this analysis.  We identified 49 PALF 
participants that met criteria for our convenience sample.  Demographics of the 49 participants 
included in this analysis are presented in Table 2.1. All participants had at least 3 and not more 
than 7 samples for analysis.  The median number of samples per patient was 4 (25th and 75th 
percentiles were 3 and 6, respectively).  The number of participants with samples tested was 18 
with 3 samples, 12 with 4, 6 with 5, 7 with 6 and 6 with 7 samples analyzed.  15 participants had 
available samples on each day from enrollment to outcome or over 7 days from enrollment.  For 
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the remainder with at least one missing sample, 3 participants had 4 missing samples, 4 participants 
had 3 missing samples, 12 participants had 2 missing samples, and 15 participants had only one 
missing sample.    
Table 2.1 Demographics, final diagnosis and outcomes of the Study Cohort 
 
 Study Cohort 
(n=49) 
         N (%) 
Age at enrollment (years) 
     Median 
     25%, 75% 
 
7.9 
1.1, 15.1  
Male 25 (51.0)  
Diagnosis 
      APAP toxicity 
      Autoimmune hepatitis 
      Viral infection 
      Indeterminate 
      Other diagnoses    
 
8 (16.3)  
5 (10.2)  
3 (6.1)  
26 (53.1)  
7 (14.3)  
Coma grade at enrollment 
       Not assessable 
       0-I 
       II-IV 
 
3  
36 (78.3) 
10 (21.7) 
21-day outcome 
      Alive without LT 
LT      
      Died without LT     
 
27 (55.1)  
15 (30.6)  
7 (14.3)  
 
2.3.3.2 Variability of circulating inflammatory mediators in PALF participants.   
Plotting individual cytokine trajectories grouped by outcome did not reveal any obvious patterns 
or characteristic properties. (See Appendix A Figs. A1.1-A1.3). Hierarchical clustering was then 
used to segregate the cytokine data based on similar dynamic patterns to determine if participants 
with similar outcomes naturally clustered together based on their cytokine values, but concluded 
that unsupervised clustering of raw cytokine measurements was incapable of predicting clinical 
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outcomes for these participants (see Appendix A.2).  Indeed, the time courses of the 26 measured 
mediators were highly variable (Fig. 2.3; Appendix A Figs. A1.1-A1.3), and standard statistical 
analyses could not segregate among SS, NS, or LTx PALF participants (data not shown).   
 
Figure 2.3 Hierarchical clustering of raw circulating inflammatory mediator data in PALF patients.  
Circulating inflammatory mediators in PALF spontaneous survivors, non-survivors, and LTx recipients 
were determined as described in the Section 2.4.3.2. Unsupervised hierarchical clustering was performed 
as described in the Materials and Methods 
2.3.3.3 Patient-Specific PCA separates some NS from SS and transplanted participants.    
We next utilized PCA to determine those circulating inflammatory mediators that dominated the 
overall patient-specific, time-dependent inflammatory profiles of the study cohort. We then 
performed hierarchical clustering on these individual inflammatory patterns and found that the 
participants segregated naturally into seven clusters (Fig. 2.4A).  The first two of these clusters 
contained only survivors (Fig. 2.4B), suggesting that the inflammatory signature common to the 
participants in those clusters might be characteristic, and perhaps predictive, of spontaneous 
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survival.  We note that the PCA and clustering analyses are both unsupervised methods, and thus 
the algorithm was blinded with regard to outcome groups. After the clustering was performed, 
cluster assignments were cross-referenced to outcomes. 
 
Figure 2.4 Hierarchical clustering of patient-specific PCA (“inflammation barcodes”) in PALF 
patients.  
The data from Figure 2.5 were subjected to patient-specific PCA (generating an “inflammation barcode”) 
followed by unsupervised hierarchical clustering as described in the Materials and Methods. Panel A: 
hierarchical clustering results, suggesting 7 distinct patient sub-groups. Panel B: Comparison of PALF sub-
groups to “inflammation barcode”-defined sub-groups. Color spectrum bar represent the number of PALF 
patients. 
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2.3.3.4 Dynamic Bayesian Network analysis segregates PALF patient sub-groups.  
The PCA/hierarchical clustering analysis suggested common inflammatory signatures may be 
associated with clinical outcomes in the study cohort. We hypothesized that these inflammatory 
patterns could reflect dynamic inflammation networks that identify key inflammatory mechanisms 
in PALF.  We therefore utilized Dynamic Bayesian Network (DBN) inference to determine if such 
networks could be discerned from the time courses of circulating inflammatory mediators in PALF 
participants.  Results of this analysis on each of the three PALF sub-groups are shown in Fig. 2.5.   
Though the data were segregated by outcome group before being subjected to DBN inference, we 
note that the algorithm makes no assumptions about the connectivity of the network in any of the 
outcome groups.  
 
Figure 2.5 Dynamic Bayesian Network analysis of inflammatory mediator data in PALF patients.  
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The data from Figure 2.5 were subjected to DBN analysis. Inflammatory mediators are shown as nodes, and the 
arrows connecting them suggest an influence of one mediator on the one(s) to which it is connected. The arrows do 
not distinguish positive from negative influences of one mediator on another.  
 
For SS: the DBN pattern suggested a network regulated via switching between the chemokines 
MIG/CXCL9 and IP-10/CXCL10, each of which drives its own expression and leads to the 
downstream production of eotaxin, sIL-2rα, MCP-1, MIP-1α, MIP-1β, and nitric oxide. In 
contrast, for NS: the DBN analysis suggested a primary network driven by the self-maintaining 
behavior of MIG/CXCL9, leading predominantly to the production of IL-6, IL-8, and nitric oxide. 
IP-10/CXCL10 was still present and driving eotaxin in this DBN, but without increasing its own 
production. A separate network consisting of MCP-1 driving IL-10 was also evident. For LTx: the 
DBN suggested a network very similar to that of spontaneous survivors, namely the apparent 
MIG/CXCL9 – IP10/CXCL10 switching with self-sustaining behavior and downstream 
production of eotaxin, sIL-2rα, IL-8, IL-10, MCP-1, and nitric oxide. To support the idea that the 
differences between groups did not arise by chance, we repeated the DBN analysis on a random 
grouping of the data and observed that the networks contained no major differences, with the core 
module of IP10/CXCL10 and MIG/CXCL9 cross-regulation and self-feedback being retained in 
all networks (Figure 2.6). 
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 Figure 2.6 DBN results from randomized outcome groups. 
Patients were grouped randomly into three groups of sizes of 27, 15, and 7 while maintaining approximately the same 
percentage of SS (55%):NS (14%):LTx (31%) in each group (panel A) or allowing the percentages to vary (panel B). 
DBNs were inferred on each group and showed no major differences, with the core module of IP-10 and MIG self-
feedback and cross-regulation being observed in all networks. Groups I, II, and III have 15, 27, and 7 patients 
respectively 
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2.3.4 Discussion 
The search for biomarkers in liver diseases has been fraught with difficulty.  Putative biomarkers 
identified in small studies are often not sufficiently disease-specific, not tied mechanistically to a 
given disease, and non-reproducible in larger studies.  Even those that are reproducible are 
frequently limited in their value to the most severe or advanced stages of disease (70-72). Recent 
studies have emphasized the need for studying multiple inflammatory biomarkers combined with 
informatics/computational techniques as a key part of the interpretation of biomarker data (15, 73-
75). This pilot study examines the use of novel analytic methods that may account for the dynamic 
complexity of the inflammatory response in PALF.  
Analysis of raw circulating inflammatory mediator data in a convenience sample of PALF 
participants demonstrated a high degree of patient-to-patient variability.  In contrast, when data 
underwent patient-specific PCA followed by unsupervised hierarchical clustering in a blinded 
fashion, seven distinct patient clusters were identified and some clusters contained only 
spontaneous survivors and LTx.  This suggests that dynamic aspects of inflammation may be 
associated with patient-specific clinical outcomes.  Finally, using DBN inference, cytokine 
networks associated with SS differed from those associated with NS.  The cytokine network 
associated with LTx had characteristics more similar to SS than NS. 
In a previous study on experimental trauma/hemorrhagic shock in genetically identical 
mice, we observed a high degree of variability in the raw circulating mediator data, but could 
identify distinct principal inflammatory drivers in animals receiving hemorrhagic shock from those 
subjected to sham cannulation (44).  In the present study, we affirm that the inflammatory response 
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of a diverse cohort of PALF participants is highly variable (76-78) and that PCA could segregate 
inflammation patterns associated with different outcomes.   
The inflammatory response can take two potential paths: (1) resolvable inflammation, in 
which the initial inflammatory response is harnessed by negative feedback that drives resolution, 
healing, and regeneration; or (2) unresolvable inflammation, which occurs when negative feedback 
is insufficient, a positive feedback loop of inflammation goes unchecked, and inflammation begets 
cellular damage and destruction which begets further inflammation (9, 14, 26, 79, 80).  Positive 
and negative inflammatory feedback with regard to ultimate health status of the patient might be 
mapped onto pro- and anti-inflammatory mediators in some contexts, but not in others. 
Furthermore, any given mediator could serve a pro- or anti-inflammatory role at a given time or 
under given conditions. Thus, using data-driven models to suggest the time and context-dependent 
role of cytokines may be more informative than relying on an analysis with static, pre-assigned 
roles for cytokines. In a prior study, our data suggested that IP-10/CXCL10 initiates a low-level, 
resolvable inflammatory response in mice subjected to minor trauma alone. In contrast, 
MIG/CXCL9 drives a more robust and potentially unresolvable inflammatory response in the 
setting of the same minor trauma + hemorrhagic shock (44).  
Several studies have demonstrated that both MIG/CXCL9 and IP-10/CXCL10 mRNA are 
elevated in experimental models of liver failure (81, 82), and circulating levels of both chemokines 
are implicated in chronic hepatitis C (83).  Importantly, and supporting our hypothesis that IP-
10/CXCL10 may drive a resolvable inflammatory response in PALF, Bone-Larson et al 
demonstrated that IP-10/CXCL10 is hepatoprotective in an experimental model of acute liver 
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injury (82). Both MIG/CXCL9 and IP-10/CXCL10 are also associated with IFN-γ signaling, a 
pathway that also influences liver regeneration.  
Based upon these preliminary studies, we hypothesized that if IP-10/CXCL10 is stimulated 
initially, then this chemokine would both drive its own production and suppress that of 
MIG/CXCL9 and lead to self-resolving inflammation. In contrast, if MIG/CXCL9 is stimulated 
initially, then MIG/CXCL9 would drive its own production while suppressing that of IP-
10/CXCL10, in turn leading to self-maintaining, or unresolvable inflammation. Based on DBN 
analysis, we found what we suspect to be a pattern of resolvable inflammation associated with SS 
and unresolvable inflammation associated with NS in our selected PALF cohort.  Specifically, we 
find PALF SS and LTx participant’s exhibit chemokines MIG/CXCL9 and IP-10/CXCL10, each 
of which exhibits feedback behavior and each of which appears to regulate the other.  This 
chemokine switching network appears to drive a diverse inflammatory response that includes 
eotaxin, sIL-2rα, MCP-1, MIP-1α, MIP-1β, and nitric oxide (in spontaneous survivors) or eotaxin, 
sIL-2rα, IL-8, IL-10, MCP-1, and nitric oxide (LTx recipients). Accordingly, we interpret the 
inflammation networks in PALF SS and LTx participants as demonstrating the possibility of 
switching between inflammatory responses driven by IP-10/CXCL10 vs. inflammation driven by 
MIG/CXCL9, and ultimately manifesting in a pattern of resolvable inflammation. In contrast, 
PALF NS participants exhibited an inflammation network that suggests feedback behavior for 
MIG/CXCL9 but not for IP-10/CXCL10, driving the production of IL-6, IL-8, and nitric oxide and 
resulting in unresolvable inflammation.  
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There are several limitations to our study. This was a retrospective study, and the identified 
networks were not validated in a separate cohort of participants. The study cohort, as well as 
sampling time points, was heterogeneous, though the participants in the study cohort were 
representative of the larger PALF Study Group cohort, and the time frame of sampling was 
restricted to 7 days post-enrollment. Only a subset of inflammatory mediators was assayed, and, 
importantly, damage-associated molecular pattern molecules (e.g. HMGB1) were not assessed.  
In conclusion, the present study suggests that the DBN-defined inflammatory networks 
might serve as powerful, new biomarkers for predicting outcomes in PALF, which represents a 
novel use of DBN inference methodology.  These findings will be validated in a larger patient 
cohort with sampling time points extending to the outcome of death, discharge, or LTx if that 
outcome was beyond seven days.   Despite a heterogeneous inflammatory response in individual 
PALF participants, our studies suggest a network-based analysis may have the potential to 
segregate spontaneous survivors and non-survivors with LTx recipients having a biomarker pattern 
more similar to spontaneous survivors than those of non-survivors.  Our data also leave open the 
possibility that these chemokine-based, feedback-driven inflammatory switching mechanisms 
might actually mediate such outcomes.  This consideration, in turn, suggests that it might be 
possible to identify subsets of PALF patients in whom specific immune-modulatory therapy might 
improve the likelihood of spontaneous survival.  
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2.4 INFLAMMATORY NETWORKS IN TRAUMA/HEMORRHAGIC SHOCK 
In this section, we use DBNs to infer the networks of inflammatory mediators in 
Trauma/hemorrhagic shock (T/HS), another condition with an inflammatory etiology that is poorly 
understood.. T/HS is the most common cause of death for young people in the U.S. and costs over 
$400 billion annually(84). Most deaths from T/HS occur due to the Multiple Organ Dysfunction 
Syndrome (MODS), a poorly understood disease that is thought to be due, in part, to dysregulated 
inflammation (85-89). We used the Dynamic Bayesian Network (DBN) algorithm described in 
Section 2.2 to define key networks of post-T/HS acute inflammation in both mice subjected to 
experimental T/HS and human trauma patients with evidence of hemorrhage. Inflammatory 
mediators were assayed in the plasma by Luminex™, and the data were subjected to DBN analysis. 
This analysis suggested a core network that involves the cytokine IL-10, as well as the chemokines 
IP-10 and MIG in mouse T/HS. In contrast, the chemokines MIG and MCP-1 and IP-10 were 
inferred as the central nodes in human trauma patients. Both cases showed network motifs 
indicative of switching between distinct inflammatory profiles driven by chemokines, suggesting 
a common core network structure that may drive divergent responses.  
2.4.1 Introduction 
Trauma and hemorrhage, like infection, are insults that induce an acute inflammatory response 
involving a coordinated mobilization of numerous cells and molecules. The complex nature of the 
response to T/HS, with its many redundant and overlapping pathways and mediators, does not lend 
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itself to a simple reductionist analysis, especially when there is limited or no experimental 
constraints on this system. We hypothesize that these multiple mechanisms of inflammation, 
operating at different time scales, contribute to the complexity of the post-T/HS inflammatory 
response. Prior studies have focused primarily on either patterns of inflammatory mediators as 
biomarkers of a particular response, or measured these mediators in cells and/or tissues. However, 
inflammatory mediators can spill out into the systemic circulation especially when the 
inflammation is dysregulated, as is the case in T/HS (6, 88, 90, 91). Thus, we focused on time 
courses of circulating inflammatory mediators in order to infer the (dis)coordination among 
inflammatory mediators in response to T/HS. Moreover, in the case of human patients, the blood 
is an easily accessible compartment for sampling.  Previous work by Mi et al shed mechanistic 
insight into the dynamic inflammatory response in T/HS in mice using statistical data-driven 
methods. In this study, we hypothesize causal networks of inflammatory mediators in mouse T/HS, 
as well as human trauma patients, inferred by Dynamic Bayesian Networks. Our results indicate 
that the inflammatory response to trauma, both with and without hemorrhage, may be directed by 
the interplay a set of key chemokines.  
2.4.2 Methods 
2.4.2.1 Mouse Model of Hemorrhagic Shock 
This study was approved by the Institutional Animal Care and Use Committee of the University 
of Pittsburgh (protocol No. 1003645) and was conducted in accordance with the National Institutes 
of Health Guidelines for the Care and Treatment of Small Laboratory Animals. Fifty-four Male 
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C57BL/6 mice (Charles River Laboratories, Raleigh, NC) weighting 25–30 grams underwent 
surgical preparation under anesthesia with isoflurane and Nembutal (70 mg/K). Animals were 
either untreated or cannulated and divided into four groups (n = 6 mice per group), subjected to 1, 
2, 3 or 4 h sham procedure (surgical cannulation trauma only; ST) or four groups of 1, 2, 3 and 4 
h of HS in addition to this surgical cannulation trauma (ST + HS). Serum was collected from mice 
sacrificed at each time point. ST + HS was carried out using a hardware/software platform for 
computerized, closed-loop HS in mice that maintains the blood pressure at below normal at 25mm 
Hg (13).  
Twenty cytokines and chemokines (basic fibroblastic growth factor [bFGF], granulocyte-
macrophage colony stimulating factor [GM-CSF], interferon [IFN]-γ, IL-1α, IL-1β, IL-2, IL-4, IL-
5, IL-6, IL-10, IL-12p40/p70, IL-13, IL-17, IP-10, Keratinocyte Chemoattractant (KC), monocyte 
chemotactic protein-1 [MCP-1], MIG, macrophage inflammatory protein-1α (CCL-3) [MIP-1α], 
TNF-α, and basic VEGF) were assessed in the serum using Luminex™ (MiraiBio, Alameda, CA) 
using the BioSource 20-plex™ mouse cytokine bead set (BioSource-Invitrogen, San Diego, CA) 
as per manufacturer's specifications. The nitric oxide reaction products NO2−/NO3− were 
assessed using the nitrate reductase kit (Cayman Chemical, San Diego, CA) as per manufacturer's 
specifications. 
2.4.2.2 Human Trauma Patients – Hypotension Cohort 
Human Trauma Patients: From a cohort of 484 blunt trauma survivors that were studied 
following IRB approval, 14 hypotensive patients (10 males and 4 females; age: 42.1±5.1; Injury 
Severity Score [ISS]:21.4±2.3) were matched with 14 normotensive patients (9 males and 5 
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females; age: 44.6±3.8;ISS: 22±2.4). Serial blood samples were obtained from all patients (3 
samples within the first 24 h and then from days 1 to 5 post-injury). The human inflammatory 
MILLIPLEX ™ MAP Human Cytokine/Chemokine Panel-Premixed 26 Plex (Millipore 
Corporation, Billerica, MA) and Luminex™ 100 IS (Luminex, Austin, TX) was used to measure 
plasma levels of interleukin (IL)-1β, IL-1 receptor antagonist (IL-1Ra), IL-2, soluble IL-2 
receptor-α (sIL-2Rα), IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, IL-15, IL-17, interferon (IFN)-γ, 
IFN-γ inducible protein (IP)-10, monokine induced by gamma interferon (MIG), macrophage 
inflammatory protein (MIP)-1α, MIP-1β, monocyte chemotactic protein (MCP)-1, granulocyte-
macrophage colony stimulating factor (GM-CSF), Eotaxin, and tumor necrosis factor alpha (TNF-
α). The Luminex™ system was used in accordance to manufacturer’s instructions. NO2-/NO3- was 
measured using the nitrate reductase/Griess assay (Cayman Chemical Co., Ann Arbor, MI). 
2.4.2.3 Network Inference 
Networks were inferred using the Dynamic Bayesian Network algorithm detailed in Section 2.2. 
For mouse data, the input for the DBN algorithm was a single time course of mean values of 
inflammatory mediators. This was done because we did not sample the serum from each mouse 
serially, but rather collected it from different mice at each time point. In contrast, because we had 
serial sampling in human patients, we ran individual DBN inference procedures for each patient, 
and reported the consensus network determined by taking the mean of the adjacency matrix for all 
patients. That is, only edges that had an average marginal posterior probability greater than 0.5 
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across all patient networks were included in the final consensus network, with the thickness of 
edges representing the averaged marginal posterior probability for that edge.  
2.4.3 Results 
DBNs inferred from mice subjected to surgical trauma (ST) with and without hemorrhagic shock 
(HS) are shown in Figure 2.3. We define central nodes, highlighted in green, as nodes with out-
degree greater than three. The network in ST portrays a response that seems to be driven mainly 
by IP-10 and MIG, with cross-interaction between them. In contrast, the ST+HS network has more 
than two central nodes: IP-10, IL-10, MIG, and FGF-B, with cross-interactions and feedback 
between several of them. When ranked by the sum of in and out degree, the highest ranking node 
was IL-10 in ST+HS and MIG in ST.  
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 Figure 2.7 Inferred Networks for Mouse ST and ST+HS 
 
In order to assess whether the results from our mouse model were clinically relevant, we 
repeated the DBN analysis on inflammatory mediators measured in human trauma patients.  As an 
indicator for the presence of hemorrhagic shock, we chose to patients who sustained low blood 
pressure (hypotensive) within the first 24 hours versus those who had normal blood pressure 
(normotensive). The patient groups were matched for age, gender, and injury-severity in order to 
remove any influence of these factors on their inflammatory profiles. Once again we observe two 
central nodes with cross-interaction between them (Figure 2.7). However, instead of MIG and IP-
10 as in the mouse study, we see the chemokines MIG, MCP-1 and IP-10 as the central nodes. In 
addition to differences in the overall set of mediators connected downstream of these central nodes, 
we note that several of the mediators common to both networks are connected to MCP-1 in 
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hypotensive but MIG in the normotensive groups (IL-Ra, IL-10, MIP-1β). This is reiterated when 
comparing the degree centrality scores, which reveal that MCP-1 is the highest ranked node in 
hypotensive whereas MIG is the highest ranked in normotensive. Importantly, we note that IL-6 
was influenced by both MIG and MCP-1 in hypotensive patients but only MIG in normotensive 
patients. 
 
 
Figure 2.8 Comparison of Networks Inferred for Hypotensive and Normotensive patients 
 
2.4.4 Discussion 
Like many other diseases, T/HS has benefited from the systems view afforded by genomic 
and proteomic studies in the past decade (92-94). Data-driven analyses of these high dimensional 
data have yielded valuable insights into the pathophysiology of T/HS but have been largely limited 
to finding associations between sets of genes or pathways and phenotypic outcomes. In this work, 
we aimed at deriving more mechanistic insight into the interaction among inflammatory mediators 
as acute inflammation progresses by inferring directed networks from time course data. A previous 
study by Mi et al on the same mouse dataset studied herein had identified MIG, IP-10, and IL-12 
 48 
as the best discriminants between ST and ST+HS using multivariate analysis (44). In our study, 
the aim was not to find discriminating factors but rather on discerning differences in the interaction 
among inflammatory mediators. These differences in network structure can provide mechanistic 
hypotheses to explain differences in the course of inflammation between the two conditions. In the 
study by Mi et al, the authors also inferred connectivity among inflammatory mediators using a 
technique termed Dynamic Network Analysis. This method is based on statistically significant 
elevation and linear correlation of mediators within particular time windows and therefore does 
not yield directed interactions like the networks inferred in this study. Regardless, the authors 
identified IP-10 as the central node in ST, and MIG, followed (in time) by KC, as the central nodes 
in ST+HS. Our DBN results suggest that MIG and IP-10 are central to both networks, but have 
different connections based on condition. In addition, our network suggests IL-10 has the most 
significant role in the mouse ST+HS network as measured by degree centrality but not in ST alone. 
This fits well with known inflammatory mechanisms in hemorrhagic shock – namely that 
hemorrhagic shock leads to an immediate catecholamine burst (95), and that these catecholamines 
directly induce expression of IL-10 (96, 97).   
Our study in the mouse model of ST+HS was specifically designed to induce shock for 1-
4 hours as that is a survivable time range for the mice. Thus, the inflammatory response to this 
insult is analogous to a survivable episode of ST+HS in humans. Accordingly, we analyzed the 
inflammatory response in human blunt trauma survivors with evidence of hemorrhage indicated 
by hypotension. Although there has been some controversy regarding correspondence between 
human and mouse inflammatory responses at the genomic level (98), we sought to determine 
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whether we could identify any similarities in network structure and interactions at the level of 
serum inflammatory mediators. The resulting networks for our human study were sparser than the 
mouse networks, although this is likely due in part to the differing method of calculating the 
consensus network (see Section 2.3.2.3). However, the role of chemokines as central mediators in 
the network remained consistent. This hypothesis is supported by the known central role of 
chemokines in acute inflammation (99, 100), including T/HS (101, 102). For a detailed discussion 
of chemokines as central mediators of the inflammatory response, see Section 2.5.  
 Taken together, our results indicate a novel role for cross-regulation among the 
chemokines MIG and IP-10 in mice and MIG, IP-10 and MCP-1 humans in directing the 
inflammatory response to trauma and hemorrhagic shock. In humans, a key difference in the 
networks of hypotensive and normotensive patients was in the addition of MCP-1 as an effector 
of IL-6. Indeed, we observed that MIG correlates with moderate levels of IL-6 whereas MCP-1 
correlates with higher levels, suggesting that modulating the effect of MCP-1 on IL-6 may lessen 
the greater inflammation induced in the setting of T/HS over trauma alone. 
2.5 SUMMARY OF ACUTE INFLAMMATION NETWORKS 
As outlined in Chapter 1, acute inflammation leads to a series of events that involve the 
coordination of several cell types via secreted/released biomolecules, in order to respond 
appropriately to stress and restore the body to homeostasis. This coordination is disrupted in many 
diseases with an inflammatory etiology, leading either to overabundant or inadequate 
inflammation. Due to the multiple conflicting roles of many cytokines dependent on timing and 
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context, we sought to infer interactions agnostically from time course data. Our primary goal was 
to generate mechanistic hypotheses that relate differences in how these mediators interact, with 
the progression of inflammation in different settings. To this end, we studied inflammation in 
response to trauma/hemorrhagic shock in mice and humans, as well as the inflammatory response 
in pediatric acute liver failure. While both of these studies generated hypotheses regarding the 
differences between groups, we also observed a repeated occurrence of two to three central nodes, 
usually chemokines, with cross regulation between them. After surveying the results from 
numerous other in vitro, in vivo, and clinical settings of both sterile and infection-induced 
inflammation, we hypothesized that there is a conserved motif of MIG, IP-10, and MCP-1 three-
way “switching” that may be responsible for directing the overall trend of the inflammatory 
response towards self-sustaining or resolving. In particular, we have observed similar networks in 
liver cells, which are a primary site of inflammatory activity during T/HS (11). DBNs inferred 
from in vitro measurements of both secreted and intracellular inflammatory mediators of mouse 
liver cells subjected to hypoxic stress identified MIG, IP-10, and MCP-1 as central nodes with 
varying connectivity depending on condition. Moreover, an extensive study of inflammation in 
multiple tissues in mouse models of infection and HS reiterated the central role for these three 
chemokines (unpublished data). The resulting central nodes of these studies, as ranked by degree 
centrality, are summarized in Table 2.2. 
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Table 2.2 Summary of Central Nodes in DBNs of Various Acute Inflammatory Settings 
 
 
There are two broad classes of chemokines, the CC chemokines that contain two adjacent 
cysteine residues, and the CXC chemokines that have a single amino acid between the two 
cysteines. CC chemokines, of which CCL2/MCP-1 is the best studied, attract monocytes to the 
site of inflammation (103). In contrast, CXC chemokines like CXCL9/MIG and CXCL10/IP-10, 
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attract polymorphonuclear leukocytes like neutrophils, and have been linked to angiogenesis. 
CCL2/MCP-1 has only one receptor, CCR2, whereas CXCL9 and CXCL10 both share a receptor 
in CXCR3 and are also both inducible by IFN-gamma. Although their functions are thought to be 
redundant, CXCL9 and CXCL10 are expressed differentially in different cell types, and have been 
implicated individually in various diseases (104, 105).  
While we observe a conserved chemokine cross-regulatory motif, the identity of 
downstream targets seems more specific to the particular inflammatory disease/setting. One 
exception is IL-6, which is always seen downstream of MIG and/or MCP-1. Indeed, a recent study 
from our group showed that IL-6 levels are significantly reduced in MCP-1 knockout liver cells 
and that high MCP-1 levels in human trauma patients correlate with high IL-6 levels (106). In 
addition, we found that MIG is associated with elevated but lower IL-6 (unpublished data). The 
assignment of induction versus suppression in the cross-regulatory interactions between 
chemokines is hypothesized based on our data that suggests that IP-10 and MIG have opposite 
effects, and supported by literature that indicates that chemokines down-regulate each other at the 
level of shared receptors (104, 107, 108). These distinctions of stimulatory versus inhibitory 
interactions may be learnt directly from the data using the method outlined in Section 2.2.1.1, or 
from iterative model refinement and validation as shown in Section 3.2. 
Based on the aforementioned observations, we hypothesize that the course of inflammation 
in a particular setting is determined by the interplay of the three chemokines MIG, IP-10 and MCP-
1, which act as a decision system that can lead to differential induction of IL-6, and subsequently, 
differential outcomes (Figure 2.9). We hypothesize that while MIG and MCP-1 have 
proinflammatory effects, IP-10 likely drives anti-inflammation leading to resolution (82). The 
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dynamic interplay of these key mediators may be responsible for the distinction between an 
appropriate pro-inflammatory response followed by anti-inflammatory activity and resolution, 
versus a self-perpetuating pro-inflammatory response that becomes dysregulated and excessive.   
 
 
Figure 2.9 Hypothesized Conserved Chemokine Switching Network 
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3.0  MECHANISTIC MODELING OF INFLAMMATION 
In the preceding chapter, we used data-driven modeling to decipher the complexity of 
multidimensional data. This is a necessary step in the comprehensive systems approach mentioned 
in Chapter 1 as it allows us to identify the essential features of a response. This is especially 
important when interpreting inflammatory mediator function. Although there is a depth of 
knowledge about particular canonical roles of inflammatory mediators, the specifics can vary 
greatly depending on tissue or even early versus later within the same compartment. It is evident 
that these functions are not necessarily uniform across time or samples (patients, animals etc.) 
even in highly controlled experimental systems as in the mouse model of T/HS discussed in 
Section 2.3. Network inference is therefore very valuable in informing causal mechanisms by 
which these biomolecules can interact. However, ultimately this inference is at most a hypothesis 
generator of mechanism that must be validated either by experimental perturbation and relearning, 
or by being encoded as a simulatable model whose predictions can be validated experimentally. 
The advantage of the latter, in addition to being able to perform in silico experiments, is that they 
also possess a rich set of tools to analyze the dynamical and steady state properties of the model. 
These analyses can shed further insight into the functional role of mediators and/or connectivity 
structures.  
In this chapter, I present two complementary studies utilizing mechanistic modeling. 
Traditionally, mechanistic models are built from a knowledge base of biochemical reaction 
pathways discovered through decades of focused research. Although such models have more 
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supporting experimental evidence to justify their structure, the assumptions built into them are not 
always clear and are not necessarily reassessed as new biology is discovered. In the case of 
abstracted interactions among inflammatory mediators, where biochemical parameterization is not 
appropriate, we chose to develop a more qualitative model using logical rules and discrete states.  
In Section 3.1, I develop a logical model based on the consensus chemokine network topology 
hypothesized by DBNs (Section 2.5). This model helps specify the details of the interactions 
inferred by DBN, and also captures a number of interesting features of the data. In Section 3.2, we 
conduct a more detailed study of a particular well-characterized biochemical signaling pathway, 
where I combine modeling and experimental studies to identify a signaling pathway that leads to 
a complex dose and time response of TGF-B1 activation by NAD+.  
3.1 BOOLEAN MODEL OF CHEMOKINE SWITCHING MOTIF 
In this study, I use manual model fitting to specify the label (activation or inhibition) as well as 
the mode of combination of interactions that best recapitulate population averaged clinical data for 
differently injured groups of patients. Despite being calibrated to the mean response, the model 
also captures differences in behaviors of subpopulations of different starting conditions within 
moderately and severely injured patients. Finally, I use a novel comparison of “time to reach steady 
state” in the model, to patient discharge rate of moderate versus severe injury. This work lends 
further support to the hypothesis that the chemokine switching motif (Figure 2.9) can account for 
and may drive the differences in trajectories in acute inflammation  
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3.1.1 Introduction 
Traumatic injury is a significant cause of morbidity and mortality in patients, especially among 
young people (84, 109). In recent years, the outcomes landscape in blunt trauma has shifted from 
mortality to secondary complications such as multiple organ dysfunction syndrome (MODS) and 
nosocomial infection, leading to a prolonged length of stay (LOS) at the hospital (110). These 
complications can be attributed in large part to the pathophysiological inflammation and immune 
dysregulation elicited after trauma/hemorrhage (85-89). Trauma/hemorrhage induces an acute 
inflammatory response that occurs at multiple scales and involves the activation of signaling 
pathways that mobilize inflammatory cells and stimulate the secretion of chemokines, cytokines 
and damage-associated molecular pattern (DAMP) molecules. Numerous studies have 
investigated this response at the level of cellular mobilization, genomic pathway activation (93), 
and secreted mediators (90, 91). Analyzing inflammatory mediators is particularly informative as 
they constitute the communication medium for organizing the response among the various cell 
types. Thus, we can discern the overall coordination of the response, and consequently, its 
dysregulation, by analyzing the dynamics of these secreted inflammatory mediators.  
Previous studies have either focused on association of dynamic patterns of inflammatory 
mediators with specific outcomes (91) or building predictive mechanistic models from prior 
biological knowledge/literature (12). In this study, we sought to identify the connectivity of 
inflammatory mediators directly from clinical data, and build a simulatable model that we could 
connect to clinical outcomes. Our aim was to go beyond the identification of patterns or 
associations with outcomes, but to identify a set of mediators and plausible mechanistic 
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interactions that can give rise to the observed inflammatory responses. We argue that the 
combination of data-driven and mechanistic insight can better inform potential therapeutic 
strategies. We inferred initial network connectivity from time-courses of serum inflammatory 
mediators using Dynamic Bayesian Networks (DBN) analysis (see Chapter 2), which identified a 
core motif of cross-regulating chemokines MIG, MCP-1 and IP-10. Building on the inferred 
network with biological mechanism and hypotheses, we constructed a logical model of this 
“chemokine switching” network, which we hypothesize represents the early control module that 
determines subsequent inflammatory trajectories. We calibrated our model to data from trauma 
patients with mild, moderate, and severe injury at the population level, and validated it by 
analyzing its performance on subpopulations with specific initial conditions. Importantly, we were 
able to connect differences in the time to resolve inflammation in the model to differences in LOS 
between moderate and severe injury groups.  
3.1.2 Boolean Modeling Background 
Mechanistic models can be classified according to the treatment of the variables as either 
continuous or discrete. However, continuous models, usually described by a set of differential 
equations, require parameterization of the kinetics of interactions. The interactions among 
inflammatory mediators that we study are abstracted interactions that function through several 
layers of signal transduction and gene regulation on different cells that ultimately leads to the 
production/activation of the target mediator. Thus, there are no measured biochemical parameters 
that define the rate or particular form of dependence between mediators. Discrete models, such as 
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Boolean modes (111-113), require little parameterization while providing a qualitative description 
of dynamics, and are thus well suited for such less-characterized systems.  
In Boolean models, each node (variable) can have only two values: 0 (OFF), indicating a 
below-threshold level of activity that is unsufficient to affect downstream nodes, and 1 (ON) which 
indicates an above-threshold activity. The logical model is defined by rules that determine the 
value of an element in relation to values for its effectors at the previous time step. An example of 
a Boolean network with corresponding rules is shown in Figure 3.1 A-B. For instance A* = B OR 
C (following the convention of Albert et al (114)) indicates that the value for A at the present time 
t will be 1 if either B or C had value 1 in the previous time step, or 0 if both B and C had value 0 
in the previous time step. It is not always clear whether interactions should integrate with AND or 
OR logic, and in the absence of experimental evidence, one may permute through several variants 
of the Boolean rules and compare the behavior of the resulting systems with real data to decide 
which is best.  
A Boolean model may be simulated with either synchronous or asynchronous update 
algorithms. Synchronous models assume that all nodes are updated at the same time, whereas 
asynchronous models update nodes in variable order.  While synchronous models are always 
deterministic, asynchronous models may be stochastic if the update order is chosen to be random 
(115, 116). The state of the whole system is expressed as a vector of individual node states, and 
by reporting the system state at each time step and mapping the allowed transitions between them, 
one can obtain a “state transition diagram”. This diagram shows how the system evolves over time 
for all possible states. As an example, the state transition graphs for synchronous and random 
asynchronous update schemes are shown in Fig 3.1 C-D. The long term behavior of the system is 
described by attractors, which may either be fixed point steady state vectors or oscillatory 
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(complex attractors) (Figure 3.1 C-D nodes marked in yellow). Although fixed point attractors are 
common to synchronous and asynchronous techniques, it may be possible for complex attractors 
to exist in only one (generally synchronous). Boolean models have been successfully applied in 
the numerous settings of both gene regulation and signal transduction(117). In this study, we use 
a discrete logical model to qualitatively model the possible trajectories of inflammatory mediators 
with an emphasis on identifying different dynamics and/or steady states of the response. 
 
 
Figure 3.1 Example Boolean Network 
3.1.3 Methodology 
From a cohort of 484 blunt trauma survivors that were studied following IRB approval, 49 mildly 
injured, 49 moderately injured, and 49 severely injured patients were matched according to age 
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and gender distribution (Table 3.1). Serial blood samples were obtained from all patients (3 
samples within the first 24 h and then from days 1 to 7 post-injury). The number and span of time 
points sampled for each patient varied, but all patients had at least three time points, all within the 
first 24 hours. Since we are focusing on how early events control the trajectory of inflammation, 
we include patients who don’t have data for later time points, as the networks inferred will reflect 
the early events that we are focusing on. The methodology for inferring DBNs is detailed in 
Chapter 2 of this thesis.  
 
Table 3.1 Demographics of human trauma patients 
 
 
 
To study the properties of the core chemokine network motif, we started our logical model 
with only MIG, MCP-1 and IP-10 elements. We connected the model to injury severity as the 
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initiating event, and IL-6 as a key output cytokine in order to compare the inflammatory dynamics 
observed in different groups of trauma patients. The elements in the model were connected as 
inferred in the DBNs. Edges were assigned as stimulating or inhibiting based on plausible 
mechanisms upon reviewing the literature, and fine-tuned to reproduce observed cytokine 
trajectories. Logic rules that defined the combination of multiple inputs were chosen in a similar 
fashion.  
We started all elements as strictly two-state Boolean variables, except injury severity which 
needed to have three states to represent mild, medium and severe injury. However, in order to 
reproduce the clinical data and avoid spurious oscillations, MCP-1, IP-10, and IL-6 were modified 
to have three states as well. Three-state elements were encoded by splitting their corresponding 
variables to “high” and “low” variables, the sum of which gives the final state for that element. 
Model simulations were run with synchronous updates and fixed injury severity but random initial 
conditions for all other variables, in order to mimic the variability of initial cytokine and 
chemokine values observed in the patient population. Since the initial states were specified as 
“random”, we ran 1000 simulations to ensure that we covered all possible permutations of initial 
states. Results are presented as mean and standard deviation of the 1000 simulations. The model 
was encoded and run using Booleannet (114).  
3.1.4 Results 
We first selected three groups of trauma patients matched for age and gender distribution but 
differing in severity of injury (Table 3.1). As expected, outcomes were worse with increasing level 
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of injury. We then sought to compare the dynamic networks of inflammation across these groups. 
Network inference by DBN showed a consistent core motif across all three groups involving the 
chemokines MIG, MCP-1 and IP-10 with cross-regulation between them (Fig 3.2 A-C). The 
interactions among cytokines in our model are not reaction mechanisms but rather representative 
of effects that involve activation and recruitment of cells as well as the intracellular signaling and 
gene regulation leading to changes in expression/secretion of target cytokines. Accordingly, and 
due to the absence of quantitative data to parameterize a reaction network model, we chose to 
construct a logical model. In contrast to reaction network models that are most often constructed 
as systems of differential equations, logical models do not require quantitative parameters. In this 
approach, the network elements are represented with discrete variables, and interactions are 
defined by logical rules. The resulting model allows exploration of dynamical and steady state 
behavior while providing qualitative comparison to experimental data.  
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 Figure 3.2 A-C DBN for Mild, Moderate and Severe Injury. D Boolean model structure 
 
To understand the dynamics of this core network, we constructed a discrete logical model 
based on these interactions with the addition of injury as a stimulus element and IL-6 as a putative 
output cytokine (Fig 3.2 D). Previous studies have shown that these chemokines can be activated 
either directly by infection and injury or indirectly through other cytokines like IFN-gamma. 
Because the parameters are integrated out during DBN structure learning, we can only translate 
the directionality of the interactions but not the sign (activation or inhibition). When constructing 
the logical model, we initially labeled the sign based on plausible mechanism from the literature 
and our own hypotheses. The labels were then adjusted as needed in order to recapitulate the 
clinically observed trajectories of the model elements. A similar approach was employed to deduce 
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the logical rules governing combinations of interactions. Thus, the model was calibrated to 
reproduce the observed population behavior of moderately and severely injured patients. 
The final set of rules for the Boolean model is given in Appendix B.1. Briefly, moderate 
injury induces IP-10 and MIG, while severe injury induces these as well as MCP-1. IP-10 has 
positive feedback on itself and both MIG and MCP-1 must be active (have value “1” or higher) to 
suppress IP-10. MCP-1 can be induced either by high injury alone, or itself, but high IP-10 
suppresses this self-feedback. MCP-1 can reach high levels only in the combination of high injury, 
moderate MCP-1 and lack of high IP-10, i.e. self-feedback is not sufficient to reach high MCP-1 
levels. Thus, the model rules clearly dictate that MCP-1 can only reach high levels in severe injury 
and also that as long is injury is severe, MCP-1 will remain at least at moderate levels even with 
high IP-10 (Figure 3.3A). MIG has self-feedback but is suppressed when both IP-10 is high and 
MCP-1 is active. IL-6 is activated by both MIG and MCP-1 but high IL-6 is induced only by MCP-
1 and suppressed by high IP-10.  When all elements are initialized to zero, they remain at zero 
(Figure 3.3B). When injury is set to moderate, IP-10 rises to high while all other variables remain 
at zero (Figure 3.3C). When injury is set to severe, IP-10 rises to high while both MCP-1 and then 
IL-6 rise to high before dropping back down to a moderate level at steady state (Figure 3.3D).  
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 Figure 3.3 General behavior of model for different baseline initial conditions. 
  
 
To mimic a population of patients starting with random baseline values of each of the 
cytokines, the model was next simulated with random initial conditions. Our simulations matched 
qualitatively with the clinical data, and importantly, were able to capture the key differences 
between MCP-1 and IL-6 trajectories of moderately and severely injured patients (Figure 3.5A-B 
vs 3.5A-B). In patients, IL-6 levels remained higher for up to day 3 in severely injured patients 
(Figure 3.5B) whereas they returned to near baseline values within the first 24 hours in moderately 
injured patients (Figure 3.5B). Correspondingly in the simulations, IL-6 reached a steady state at 
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low levels within the first 5 time-steps for moderate injury, whereas it spiked and maintained at 
higher levels until reaching steady state at 6 time-steps for the severe injury case. Notably, the IL-
6 trajectory in the simulations maintained at a medium steady state whereas in the patients it did 
come down to baseline once again. For MCP-1 we observed a monotonic decrease to a lower level 
in moderately injured patients whereas there was a sharp spike and settling at a higher level for 
severely injured patients. Accordingly, the simulations for MCP-1 showed the same behavior. 
MIG and IP-10 trajectories did not differ qualitatively between moderate and severe injury groups 
and the simulations matched closely with them. However, the simulations for IP-10 showed a 
monotonic rise to a steady state high level whereas in the patients, there was an early dip and 
delayed rise.  
In order to address the discrepancy in the IP-10 simulations, we hypothesized an additional 
node (labeled X) positioned upstream of IP-10 that may delay its induction by injury. We examined 
both spiky (Figure 3.6A) and sustained (Figure 3.6B) dynamics of element X and observed that 
the IP-10 trajectory corresponding to the latter most closely fit our clinical data (Figure 3.6C and 
Figure 3.6D vs Figure 3.6E). We compared this trajectory for element X to the other inflammatory 
mediators measured and found that it matched most closely to IFN-gamma, the putative inducer 
of IP-10. 
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   Figure 3.4 Cytokine trajectories for Moderate Injury – Patients vs Simulations 
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 Figure 3.5 Cytokine trajectories for Severe Injury – Patients vs Simulations 
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 Figure 3.6 Addition of Node X Improves IP-10 Simulations 
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We next tested whether subpopulations with specific initial conditions also resulted in 
simulations that matched clinically observed cytokine trajectories. As the model was calibrated to 
overall population behavior with random initial conditions, we consider this a form of validation. 
A previous study from our group had shown that trauma patients segregated by MCP-1 levels show 
significant differences in outcomes. Therefore, we chose the threshold used in that study of MCP-
1 levels lower than 1000 pg/ml to correspond to an initial condition of low MCP-1. We compared 
the responses of patients with low MCP-1 under moderate or severe injury and observed that MCP-
1 levels were significantly higher in patients with severe injury compared to moderate injury 
(P<0.05, 2-way ANOVA, Figure 3.7B vs 3.7D). Correspondingly, model simulations showed that 
under moderate injury, MCP-1 levels remained at a lower level than under severe injury when 
starting with the same initial condition of MCP-1 low (Figure 3.7A vs Figure 3.7C).  
 
Figure 3.7 Model captures differences in Moderate vs Severe Injury Patients with low MCP-1 
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Figure 3.8 State transition graphs for Severe and Moderate Injury Simulations. 
 
Although there was only one steady state for each injury severity, we investigated whether 
the time to reach that steady state varied depending on initial conditions by examining the state 
transition graphs for the logical model (Figure 3.8). Our simulations are deterministic, so there is 
only one path from each initial state to the final steady state. For severe injury, all initial states also 
take the same number of steps to reach the steady state. However for moderate injury, different 
clusters of initial states take varying number of steps to reach the steady state. We compared this 
behavior to patient discharge as a clinical metric analogous to reaching steady state (Figure 3.9). 
Although we did not observe a sharp time of discharge for severe injury patients as in the 
simulations, the model was able to capture the earlier discharge of moderate injury patients.  
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 Figure 3.9 Model captures differences in Patient Discharge in Moderate vs Severe Injury Patients 
 
3.1.5 Discussion 
Most evidence suggests that either insufficient (7) or self-sustaining (118) inflammation drives the 
pathobiology of trauma/hemorrhage and subsequent processes such as nosocomial infection-
induced sepsis. Acute inflammation due to traumatic injury represents a highly complex and 
coordinated response. We hypothesized that the coordination of inflammatory mediators early in 
the response dictates the subsequent trajectory and speed of resolution. By studying 
demographically matched groups of trauma patients with mild, moderate, or severe injury, we 
aimed to elucidate the mechanisms by which their corresponding inflammatory responses differed. 
Accordingly, we applied DBNs to infer the inflammatory networks across injury severity. Our 
results showed that over a broad range of ISS, the core chemokine motif persists. Interestingly, IL-
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6 received more connections as severity of injury increased, i.e. for mild injury IL-6 only received 
input from MIG, whereas for moderate it was both MIG and MCP-1 and for severe it was MIG, 
MCP-1 and IP-10. In the absence of experimental perturbations to validate the model, we used 
trajectories of subgroups to show that the model can capture a range of dynamics that were 
observed in the patients instead of just the mean behavior that it was calibrated to.   
Our most interesting result came from analysis of the state transition diagrams. These 
suggested that in the setting of moderate injury, initial conditions of the inflammatory mediators 
can determine how long it takes to reach the (resolving) steady state. In contrast, all trajectories 
reached steady state at the same time point under severe injury. This suggests that severity of injury 
may trump individual differences in baseline inflammatory mediators.  
 There are a number of limitations to this study. The proposed logical model is not the only 
network that can give rise to the observed data and therefore does not represent a unique solution. 
Since the network is relatively small, a more rigorous effort to quantify model uncertainty can be 
made by permuting through all possible Boolean functions based on the network topology (i.e. 
combinations of AND/OR/NOT logic) and measuring the output of these models compared to the 
patient data. Alternatively, one may use Probabilistic Boolean Networks to determine the 
robustness of the model behavior to varying the logical functions encoding interactions (119). In 
addition, although we are modeling resolution of inflammation, we are not modeling healing. We 
assume that injury is present throughout and therefore affects the activation of the chemokines 
equally throughout the time course. Also, resolution of inflammatory mediators as determined by 
steady state in the model does not necessarily correspond to discharge, as there are many other 
clinical factors besides inflammatory condition that determine discharge. More work needs to be 
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done to solidify the connection between the steady state of inflammatory molecules and patient 
discharge. Lastly, the choice of synchronous updates may not be appropriate for this case. We 
assume that the events leading to the activation or suppression of one cytokine on another all 
involve cell migration, signaling, and gene transcription and therefore operate over relatively long 
timescales and are therefore similar across each cytokine-cytokine interaction. However, it is 
possible that these cytokines interact in more direct ways as well that may be on faster timescales 
– indicating that interactions follow a particular order (rank order updates) or take into account 
stochastic effects (asynchronous updates). Indeed, there is evidence to suggest that the interaction 
among chemokines may be occurring at the level of competition for shared receptors, a relatively 
fast process (104, 107, 108). A more thorough characterization of the biochemistry of interactions 
among cytokines can inform the appropriate choice of update scheme and also help refine the 
logical rules in the model. 
3.2 TRANSFORMING GROWTH FACTOR- Β1 REGULATION BY 
EXTRACELLULAR NAD+ 
This section is taken from a paper published in Journal of Biological Chemistry (120). In this work, 
we characterized a novel mechanism of induction and activation of TGF-β1 by NAD+. We 
characterized the signaling pathway by with NAD+ mediates this induction through combined 
experiment and mathematical model refinement. My role in this study was to design and perform 
experiments in combination with differential equation model design, analysis and refinement in 
 75 
order to investigate the mechanism for the complex dose and time dependent response of TGF-β1 
activation and induction by NAD+.  
3.2.1 Introduction 
Inflammation is a complex process in which various potent mechanisms that can control infection, 
injury, and proliferative diseases must be kept in check (8). Studies over the past decade have 
focused on the release of damage-associated molecular patterns (DAMPs) from cells, a class of 
molecules that signal a disruption of cellular homeostasis. Prototypically, these DAMPs are 
proteins or other cellular constituents that carry out housekeeping functions normally, but are 
released in settings of stress, inflammation, or injury. In turn, these agents stimulate, propagate, or 
potentiate both innate and adaptive immune responses (121). Recent studies have suggested that 
one such mediator may be β-nicotinamide adenine dinucleotide (NAD+), a ubiquitous cellular 
constituent that is used by cells as an electron acceptor (or, in its reduced form, NADH, as an 
electron donor) in a wide variety of enzyme-catalyzed redox reactions. These actions of NAD+ 
occur in multiple cell types secondary to the formation of cyclic adenosine dinucleotide ribose 
(cADPR) from NAD+, with subsequent release of Ca2+ (122). Importantly, NAD+ has been found 
to exert a profound anti-inflammatory activity that it appears to share with nicotinamide (123). 
The mechanisms by which these anti-inflammatory actions are carried out, however, remain poorly 
understood. 
Transforming Growth Factor β1 (TGF-β1) is a cytokine that belongs to a family of three 
related isoforms, all of which exert crucial biological functions. Of these three isoforms, TGF-β1 
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is the most prominent in the control of inflammation and immunity (124). The numerous biological 
functions of all TGF-β’s require a set of post-translational modifications termed “activation.” The 
bioactive forms of all TGF-β’s are 25 kDa homodimers produced from ~50 kDa monomers that 
dimerize to form the ~100 kDa TGF-β precursor. This precursor is cleaved intracellularly by furin 
proteases to yield the 25 kDa active TGF-β dimer, which remains associated with the remaining 
portion of its own pro-form, the latency-associated peptide (LAP, ~75 kDa). This complex is 
termed “latent TGF-β,”and is secreted in this form. Other proteins, such as latent TGF-β binding 
proteins (LTBP, which targets TGF-β’s to the extracellular matrix) or α2 macroglobulin (which is 
associated with circulating TGF-β1) can bind to this complex, creating the so-called large latent 
complex. Latent TGF-β is activated by a process that involves dissociation and degradation of 
LAP by proteins (e.g. plasmin and transglutaminase), heat, chaotropic agents, acid, as well as 
oxygen and nitrogen free radicals. Though TGF-β1 can auto-induce its own expression at the 
mRNA level, the post-translational control of TGF-β1 through activation is arguably the most 
potent regulatory mechanism for this cytokine (125, 126). 
As early as 1978, an “NAD+-splitting enzyme” was reported in macrophages (127-
129).Since cytokines, radiation, and free radicals can lead to the activation and increased 
expression of latent TGF-β1 in macrophages (130-133), we hypothesized that extracellular NAD+ 
could exert a similar effect. We further hypothesized that the mechanism by which NAD+ would 
act would involve the generation of cADPR from extracellular NAD+. Finally, we hypothesized 
that cADPR would exert its effects via the stimulation of Ca2+. In order to better understand the 
complex interplay among NAD+, cADPR, Ca2+, active and latent TGF-β1, we constructed both 
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statistical and mathematical models and validated some predictions from these models in vitro. 
These computational models also suggested the existence of as yet unknown mechanisms by which 
NAD+ can augment TGF-β1.Taken together, our results demonstrate a novel pathway for TGF-β1 
activation via NAD+ and its metabolites, and highlight the utility of mathematical modeling for 
discovering novel biological mechanisms. 
3.2.2 Methods  
3.2.2.1 Cell culture and experimental treatments 
RAW 264.7 mouse macrophage-like cells (American Type Culture Collection, Manassas, VA) 
and primary peritoneal macrophages isolated from C3H/HeJ (TLR4-mutant, n=8 animals) and 
C3H/HeOuJ (wild-type controls for C3H/HeJ, n=8 animals) mice (The Jackson Laboratory, Bar 
Harbor, ME) were cultured and plated in DMEM + 1% FBS containing L-glutamine and penicillin/ 
streptomycin. The FBS used was previously determined to have the lowest levels of TGF-β1 of 
various manufacturers and lots (data not shown), in order to minimize the exposure of cells to 
TGF-β1 that could auto-induce further expression of TGF-β1. The cells were cultured in 1% FBS 
since this was the lowest concentration of serum that allowed for cell proliferation while 
minimizing exposure to TGF-β1. The passage number was kept <18 for the same reason: as the 
passage number increased, the basal immunocytochemical expression of both active and latent 
TGF-β1 increased (data not shown). The cell culture and semi-quantitative immunocytochemical 
detection of active and latent TGF-β1 have been described previously (134). In brief, the cells 
were plated in eight-well Lab Tek™ Chamber Slide™ tissue culture plates (NalgeNunc 
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International, Rochester, NY), which allowed for several experimental conditions per well and 
also for immunocytochemistry at the end of the culture period. The cells were plated at a 
concentration of 2x105 cells/ml in 500 µL and were maintained in 5% CO2 in a humidified 
atmosphere until adherent. The cells were then treated with either NAD+ or 3-cADPR, in the 
presence or absence of other pharmacological agents, and analyzed for active/latent TGF- β1 as 
indicated. In those experiments where Ca2+ antagonists were used, the medium was removed 
before further treatment with the Ca2+ agonists or NAD+ as indicated. For time-course experiments, 
the cells were treated with NAD+ and were left to incubate at 37°C for 1, 2, 6, 8, 12, or 24 h and 
then processed for immunocytochemistry as described previously (134). Each treatment was 
carried in duplicate, in order to allow for the eventual parallel immunocytochemical detection of 
active and latent TGF- β1 (see below). 
3.2.2.2 Immunocytochemistry 
 In previous studies on TGF-β1 activation in macrophages, we utilized dual immunofluorescence 
to detect active vs. latent TGF-β1 (132, 135). However, we found that NAD+ caused macrophages 
to auto-fluorescence in a dose-dependent manner, and this artifactual effect confounded our ability 
to detect active and latent TGF-β1 (data not shown). Accordingly, we carried out separate 
immunostaining for active and latent TGF-β1 using the DAB method, as described previously 
(134). In brief, at the conclusion of the incubation period, the cells were fixed in 70% ethanol for 
30 min. Endogenous peroxidases were inhibited using 0.3% hydrogen peroxide solution for 30 
min. Non-specific antibody reactivity was blocked as follows. The wells that were stained for 
active TGF-β1 were blocked with 1.5% goat serum, while the wells stained for latent TGF-β1 were 
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blocked with 1.5% rabbit serum; all blocking was performed for 20 min. The cells were then 
incubated with primary antibody specific for either active TGF-β1 (chicken anti-human active 
TGF- β1) or latent TGF-β1 (goat anti-human latent TGF-β1) for 30 min. The cells were then 
incubated with secondary antibodies as follows. For wells being stained for active TGF-β1, the 
secondary antibody solution consisted of approximately 0.5% goat anti-chicken antibody, mixed 
with 1.5% goat serum and 1 mL PBS. For wells being stained for latent TGF-β1, the secondary 
antibody solution consisted of 0.5% rabbit anti-goat antibody mixed with 1.5% rabbit serum and 
1 mL PBS. The incubation time for the secondary antibody was 30 min. The cells were then 
exposed to the ABC enzyme conjugate for 30 min, after which they were stained with a 
diaminobenzidene (DAB) brown stain for 90 sec. The cells were then incubated with a 
hematoxylin blue counterstain for 20 sec. The slides were then dehydrated and cleared in a series 
of graded ethanol solutions (one wash in 70%, two washes in 95%, and two washes in 100%), 
followed by one wash in xylene. The slides were then dried overnight and mounted with 
Permount™ (Fisher Scientific, Pittsburgh, PA). 
3.2.2.3 Quantification of immunocytochemistry 
Quantification of active/latent TGF-β1 immunostaining was carried out as described previously 
(134). In brief, three images from each well were captured using a Zeiss Axioskop 40 (Göttingen, 
Germany) equipped with a digital camera and Motic Image 2000® software. The images were 
captured at 400x magnification, and were analyzed using the Image J™ 1.35c freeware (NIH, 
Bethesda, MD) and the Color Inspector 3D plugin. Since the two primary colors in each picture 
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were brown and blue, data were gathered using a brown to blue ratio. Due to the DAB brown stain, 
the color brown indicated presence of TGF-β1, while the color blue, from the hematoxylin counter-
stain, indicated the absence of TGF-β1. We used the histogram setting in Color Inspector 3D in 
order to cluster similar color values, thus simplifying the quantification process. We then 
determined different values to mean “blue” or “brown” and counted the percentage of the screen 
taken up by pixels that fell under the “blue” category or the “brown” category. The ratio of brown 
positive/blue positive cells in 2-3 fields per image was calculated utilizing the following formula:  
Brown-to-blue ratio = (Sum 2-3 fields brown/Sum 2-3 fields blue) x 100 [%] 
Each complete immunocytochemistry assessment was repeated at least three 
times/experiment and the mean brown positive/blue positive ratio was calculated. A higher brown-
to-blue value indicates a higher cell-associated expression of either active or latent TGF-β1. In 
some experiments, the final values for active or latent TGF-β1 were determined as fold change 
(vs. non-treated control cells) ± SEM of at least three independent experiments as indicated. 
3.2.2.4 Northern Blot analysis 
Total RNA was isolated from treated and control RAW 264.7 cells using an UltraSpec™ RNA 
isolation reagent from Biotecx Laboratories, Inc. (Houston, TX). Northern blot analysis of TGF-
β1 mRNA levels was carried out using a 1.6-kb TGF-β1 cDNA probe derived from the mouse 
full-length sequence (Image clone #3586216 from Invitrogen, Carlsbad, CA, Accession 
#BC013738) after Xba 1 and Sal 1 digestion as described previously (134). This probe cannot 
distinguish between active and latent TGF-β1. 
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3.2.2.5 Statistical analysis 
All data are presented as means ± SEM of n number of independent experiments as shown in each 
Figure Legend. Unless otherwise indicated the data were analyzed by one-way analysis of variance 
(ANOVA) followed by a post hoc test (Student-Newman-Keuls Method) as appropriate using 
SigmaPlot for Windows Version 11.0 (Systat Software Inc., San Jose, CA).  
3.2.2.6 Statistical model 
A statistical model was generated from the dose-curve and time-course data. The responses of 
active and latent TGF-β1 could be explained by two independent variables, concentration of NAD+ 
(values of 0, 10, 100 or 1000 µM) and time (values of 1, 2, 4, 6, 8, 12, or 24 h). At each 
(concentration, time) pairing, 5-7 independent observations (experimental repeats) were ultimately 
obtained; some outliers were omitted. These responses were modeled as a bivariate Gaussian 
vector, and the explanatory (independent) variables were interpreted as ordered factors. 
Orthogonal polynomial contrasts were used as columns of the factorial design matrix. Various 
possible model choices were explored, and second-degree polynomial fits with interactions 
provided a good explanation of the data. Specifically, we allowed linear and quadratic effects in 
concentration and time, as well as possible interactions between these effects. 
3.2.2.7 Differential equation model 
The system was modeled in Matlab® using ordinary differential equations (ODEs) with mass 
action kinetics for the following 7 variables: N (NAD+), C (Ca2+), Tl (Latent TGF-β1), Ta (Active 
TGF-β1), Tm (TGF-β1 mRNA) and X1 and X2 (unknown intermediaries). All variables were 
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presumed to have exponential decay rates. In addition, the following interactions were included in 
the ODEs:  
• NAD+ is consumed to produce Ca2+ 
• Latent TGF-β1 is produced by translation from TGF-β1 mRNA and consumed by the 
Ca2+ catalyzed conversion to active TGF-β1 
• Active TGF-β1 is produced by the Ca2+-catalyzed conversion from latent TGF-β1, and is 
consumed by a threshold-dependent constant rate 
• The variables X1 and X2 represent a conglomeration of the intermediary steps going 
from NAD+ signaling to TGF-β1 mRNA induction 
• X1 is produced according to a Hill function of NAD+ and X2 is produced by X1 
• TGF-β1 mRNA is subsequently produced by X2 
The parameters of the model were estimated manually such that the latent TGF-β1 response 
becomes dose-dependent at approximately 12 h, as observed experimentally. 
3.2.3 Results 
3.2.3.1 NAD+ increases the expression of active and latent TGF-β1 in RAW 264.7 
macrophage-like cells  
We first tested the hypothesis that treatment of macrophages with extracellular NAD+ would lead 
to increased expression of both active and latent TGF-β1 in macrophages, utilizing the RAW 264.7 
mouse macrophage-like cell line. Various studies have suggested that the activation of latent TGF-
β1 is often best assessed immunocytochemically (132-134), and so we utilized this method 
initially. In prior studies (134), we have shown concordance between immunoblotting and this 
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immunocytochemistry-based method of differential detection of active vs. latent TGF-β1. As 
shown in Fig. 3.9, treatment with 10-1000 µM NAD+ for 2 h led to a dose-dependent increase in 
immunocytochemically detectable latent (Panels B-D) and active (Panels F-H) TGF-β1 compared 
to control resting cells (Panels A and E).  
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 Figure 3.10 Increased expression of active and latent TGF-β1 protein induced by NAD+ in RAW 264.7 
macrophage-like cells.  
Mouse RAW 264.7 cells were either incubated with medium alone (Panels A and E) or were treated with 10, 
100, or 1000 µM NAD+ for 2 h (Panels B-D and F-H) as indicated, and subsequently immunostained for 
latent (Panels A-D) or active (Panels E-H) TGF- β1 
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3.2.3.2 NAD+ and its extracellular metabolite cADPR increase the expression of active and 
latent TGF-β1 in primary mouse peritoneal macrophages 
We next sought to confirm in primary macrophages the basic finding of NAD+/cADPR-mediated 
increase in TGF-β1, and to determine whether or not the effect of NAD+/cADPR was due to LPS 
contamination, again using our previously published immunocytochemical method coupled with 
image analysis and quantification (134). 
As seen in Figure 3.10, treatment with either 100 µM NAD+ or 10 nM of the stable cADPR 
analog 3-deaza-cADPR (136) for 1 h led to increased active (Figure 3.10A-B) and latent TGF-β1 
(Figure 3.10C) in isolated peritoneal macrophages from both wild-type (C3H/HeOuJ) and LPS-
hyporesponsive, TLR4-mutant (C3H/HeJ) mice at 1 h post-treatment. Moreover, there were no 
statistically significant differences between C3H/HeJ and C3H/HeOuJ macrophages with regard 
to expression of NAD+/cADPR-induced active TGF-β1 (Figure 3.10B). Taken together, these 
results show that NAD+ and 3-cADPR can induce and activate TGF-β1 in primary macrophages 
in vitro, and strongly suggest that LPS contamination is at most an extremely minor contributor to 
the effects of NAD+ and 3-cADPR on TGF-β1. 
3.2.3.3 The extracellular NAD+ metabolite cADPR increases the expression of both active 
and latent TGF-β1 in RAW 264.7 macrophages 
As seen in Figure 3.11A, treatment with 100 µM NAD+ for 2 h led to increased active TGF-β1. 
To determine if this effect of NAD+ depends on the prior conversion to cADPR (122), we treated 
RAW 264.7 cells with NAD+ in the presence of the stable, cell-permeable cADPR antagonist 8-
Br-cADPR (137). As seen in Figure 3.11A, 10 uM 8-Br-cADPR antagonized the effect of NAD+ 
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on both active and latent TGF-β1. We also observed a significant expression of active (but not 
latent) TGF-β1 induced by this dose of 8-Br-cADPR, which we hypothesize is due to an off-target 
effect of this compound. 
 
 
Figure 3.11 Increased expression of active and latent TGF-β1 protein induced by NAD+ and its 
extracellular cADPR in primary mouse peritoneal macrophages.  
Isolated peritoneal macrophages from both wild-type (C3H/HeOuJ) and the TLR4-mutant (C3H/HeJ) mice 
were either incubated with medium alone (Control) or were treated with NAD+ (100 µM) or the cADPR 
analogue 3-cADPR (10 nM) for 1 h as indicated, and subsequently immunostained for active (Panels A-B) 
or latent (Panel C) TGF-β1. (Panel A: *P<0.05 vs. Ctrl HeJ, **P<0.05 vs. Ctrl HeOuJ; Panel B: *P<0.05 vs. 
Ctrl HeJ, **P<0.05 vs. Ctrl HeOuJ, #P=0.005 vs. NAD+  HeJ, analyzed by one-way ANOVA followed by 
Tukey test). 
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We next sought to further define the TGF-β1 response of RAW 264.7 cells to cADPR. As seen in 
Figure 3.12B, authentic cADPR (10 µM) led to increased expression of both active and latent 
TGF-β1. Similarly, the stable cADPR analog 3-deaza-cADPR (136) (which is much more stable 
than authentic cADPR) also led to increased expression of both active (Figure 3.12C) and latent 
TGF-β1 (Figure 3.12D) at concentrations of 1-50 nM. 
 
Figure 3.12 cADPR increases the expression of both active and latent TGF-β1.  
(A) RAW 264.7 cells were treated with 100 µM NAD+ for 2 h with or without 30 min pretreatment with 8Br-cADPR 
(10 µM) as indicated, and subsequently immunostained for active and latent TGF-β1 as described in the Materials 
and Methods (n=5, *P<0.05 vs. Ctrl and NAD++ 8Br-cADPR, **P<0.05 vs. Ctrl and NAD+ + 8Br-cADPR for active 
TGF-β1). (B-D) RAW 264.7 cells were treated with 10 µM authentic cADPR (Panel B) or with 1, 10 and 50 nM 3-
cADPR for 30 or 60 min (Panels C-D) as indicated, and subsequently immunostained for active or latent as described 
in the Materials and Methods. Panel B: n=3, *P<0.001 vs. 0 µM at 60 min, analyzed by Student’s t-test. Panel C: 
n=7, *P<0.05 vs. 0 nM at 30 min, **P<0.05 vs. 0 nM at 60 min; Panel D: n=8, *P<0.05 vs. 0 nM at 30 min). 
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3.2.3.4 The effects of NAD+ and cADPR on TGF-β1 require Ca2+ mobilization, are mimicked 
by Ca2+ agonists, and are inhibited by Ca2+ antagonist  
cADPR has been reported to lead to the release of Ca2+ from ryanodine-sensitive intracellular 
stores (122). Accordingly, we further probed this pathway in the response to NAD+. We found 
that blocking Ca2+ with the Ca2+ chelator BAPTA (10 µM) inhibited the activation of TGF-β1 by 
100 µM NAD+ (Figure 3.13A) at 1 h and to a lesser degree at 3 h (Figure 3.13B). Furthermore, 
treatment with the cADPR analogue 3-cADPR (1 nM, Figure 3.14A), the Ca2+ agonists bradykinin 
(10 µM, Figure 3.14B) or ionomycin (1 µM, Figure 3.14C) for 1 h induced increased active and 
latent TGF-β1, an effect inhibited by pretreatment for 30 min with the Ca2+ chelator BAPTA. The 
involvement of Ca2+ mobilization in the activation of TGF-β1was further investigated using the 
L-type calcium channel blocker verapamil. We found that pretreatment of macrophages with 100 
µM verapamil for 30 min resulted in a significant inhibition of NAD+-induced activation of TGF-
β1 (Figure 3.14D), though this drug had no effect on the immunostaining for latent TGF-β1. 
 89 
 Figure 3.13 The effects of NAD+ on TGF-β1 are inhibited by Ca2+ antagonism.  
RAW 264.7 cells were pretreated with or without the Ca2+ chelator BAPTA (10 µM) for 30 min followed by incubation 
in media alone or media containing 100 µM NAD+ for 1 h (Panel A) or 3 h (Panel B) as indicated. The cells were then 
immunostained for active and latent TGF-β1 as described in the Materials and Methods (Panel A: n=6, *P<0.001 vs. 
Ctrl, BAPTA and BAPTA + NAD+ for both active and latent TGF-β1; Panel B: n=6, *P<0.001 vs. Ctrl and BAPTA, 
#P=0.001 vs. BAPTA + NAD+, **P<0.001 vs. Ctrl and BAPTA for active TGF-β1; $P<0.05 vs. Ctrl, BAPTA and 
BAPTA + NAD+, $$P<0.05 vs. Ctrl and BAPTA for latent TGF-β1). 
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 Figure 3.14 The effects of cADPR on TGF-β1 require Ca2+ mobilization, are mimicked by Ca2+ agonists, and 
are inhibited by Ca2+ antagonism.  
RAW 264.7 cells were pretreated without or with the Ca2+ chelator BAPTA (5 µM Panel A or 10 µM Panels B and 
C) or the L-type calcium channel blocker verapamil (100 µM, Panel D) for 30 min followed by incubation in media 
alone or media containing 1 nM 3-cADPR (Panel A), 10 µM bradykinin (Panel B), 1µM ionomycin (Panel C) or 100 
µM NAD+ (Panel D) for 1 h as indicated. The cells were then immunostained for active and latent TGF-β1 as described 
in the Materials and Method (Panel A: n=12, *P<0.05 vs. Ctrl, BAPTA and BAPTA + 3-cADPR for both active and 
latent TGF-β1; Panel B: n=6, *P<0.05vs. Ctrl, BAPTA and BAPTA + bradykinin for both active and latent TGF-β1; 
Panel C: n=6, *P<0.05 vs. Ctrl, BAPTA and BAPTA + ionomycin for both active and latent TGF-β1; Panel D: n=7, 
*P<0.001 vs. Ctrl and verapamil, **P=0.015 vs. verapamil + NAD+, #P=0.031 vs. Ctrl for active TGF-β1. One-way 
ANOVA for latent TGF-β1 resulted in an overall significance of P=0.02). 
 
3.2.3.5 The effect of NAD+ on active and latent TGF-β1 follows a complex dose and time 
course  
We next carried out a detailed dose- and time-course study of the effects of NAD+ on the 
immunocytochemically detectable expression of active (Figure 3.15A) and latent TGF-β1 (Figure 
3.15D). This study suggested that the effect of NAD+ on both active and latent TGF-β1 was 
complex and possibly biphasic. NAD+ led to the activation of latent TGF-β1 at early time points 
 91 
(1-2 h), which declined by 6 h and then appeared to rise again towards 24 h. The effect on latent 
(total) TGF-β1 was similar but shifted in time, with the peak effect of NAD+ on latent TGF-β1 
occurring at 6 h and then declining by 12 h. This study also suggested that the effect of NAD+ on 
active TGF-β1 was dose-dependent from 10-1000 µM at late time points (8-24 h) post-stimulation, 
but peaked at 100 µM and declined at 1000 µM at early time points (1-6 h). The effects on NAD+ 
on latent TGF-β1 were similar but again appeared to be shifted in time, with dose-dependent 
increases of latent TGF-β1 apparent at 1, 12, and 24 h but with a peak at 100 µM at 2-8 h. 
3.2.3.6 Statistical and mathematical modeling of the complex effects of NAD+/cADPR/Ca2+ 
on TGF-β1 
To gain insight into the complex dose- and time-courses described above, the responses were 
modeled statistically (see Figure 3.15B,E) as a bivariate Gaussian vector (see 3.2.2.6). The 
expected value of active TGF-β1 was modeled as 
 
E(active TGF-β1) = 1.74 + 0.75Cl – 0.5Cq + 0.49Tq + 1.07CqTl - 0.8CqTq 
Upper bounds on the p-values of these coefficients based on t-tests and read from left to right 
are, respectively, 0.0001, 0.0001, 0.005, 0.025, 0.015, and 0.068. The model-based estimate for 
the variance was S2=1.09 on 142 degrees of freedom. The R2 was 0.233. The hypothesis that there 
are no effects whatsoever upon this response was rejected based on an F-test with F-value of 5.38 
on 8 and 142 degrees of freedom and a p-value of 0.00000644. From this model, we concluded 
that active TGF-β1 is significantly influenced primarily by the concentration of NAD+, which 
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manifests both linear and quadratic influence, by a quadratic effect of time, and by two significant 
concentration-time interactions. 
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Figure 3.15 Complex dose- and time-course of the expression of active and latent TGF-β1 in RAW 264.7 cells 
treated with NAD+.  
RAW 264.7 cells were treated with 0, 10, 100, or 1000 µM NAD+ for 0-24 h as indicated, and subsequently 
immunostained for active (Panel A) or latent (Panel D) TGF-β1. The results are mean ± SEM of 5-7 experiments. 
(Panel A: *P<0.05 vs. 0 µM NAD+, #P<0.05 vs. 100 µM NAD+ at 1 h; Panel D: *P<0.05 vs. 0 µM NAD+, #P<0.05 
vs. 100 µM NAD+ at given time point, ^P<0.05 vs. 10 µM NAD+ at 1 h, $P<0.05 vs. 100 µM NAD+ at 6 h, analyzed 
by one-way ANOVA followed by the Fisher LSD method). Values generated by a Statistical model and a non-linear 
ODE model are shown in Panels B-C for active TGF-β1 and in Panels E-F for latent TGF-β1. Time-points in boxes 
(Panels B-F) represent good concordance with experimental data. 
 
Dependence of latent TGF-β1 on NAD+ was deemed to be simpler, in the sense that 
interactions between concentration and time were not required in the model. Indeed, in this case 
we obtained a purely linear dependence. The following equation describes the relationship 
between latent TGF-β1, NAD+ concentration, and time: 
 
E(latent TGF-β1) = 1.85 + 0.97Cl – 0.5Cq – 0.35Tl 
 
The analogous p-values, read from left to right, are lower than the respective values of 0.0001, 
0.0001, 0.005, and 0.108. The model-based S2 is 1.08 on 142 degrees of freedom, with an R2 of 
0.238. The hypothesis of no effects of concentration and time upon latent is rejected based on an 
F-value of 5.554 on 8 and 142 degrees of freedom with a p-value of 0.000004051. This statistical 
model suggested that the effects of NAD+ on TGF-β1 were nonlinear and this model was capable 
of predicting not only the levels of active (Figure 3.15B vs. 3.15A) and latent TGF-β1 (Figure 
3.15E vs. 3.15D) but also the biphasic dose effect of NAD+. 
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 Figure 3.16 ODE Model Refinement.  
 
In order to help define the mechanism by which NAD+, cADPR, and Ca2+ led to the 
induction and activation of TGF-β1, we sought to create a mechanistic mathematical model of the 
presumptive interactions among these variables. Based on these data-driven modeling studies, we 
inferred that the effects of NAD+ on TGF-β1 are non-linear. Accordingly, we created a non-linear 
ODE model of interactions we considered the most parsimonious and yet still capable of 
recapitulating the complex biological phenomena described above. Our initial ODE model 
included the interactions depicted in Figure 3.16B which shows NAD+ signaling through cADPR 
and Ca2+ to activate TGF-β1, which can then auto-induce its own mRNA production. However, 
this initial model was unable to account for the apparent second rise in TGF-β1 observed at the 
later time-points in Figure 3.15A and 3.15D. Importantly, we sought to include a mechanism by 
which BAPTA could suppress the NAD+-induced increase in both active and latent TGF-β1 at 1 h 
(Figure 3.14A), but to a lesser extent at 3 h (Figure 3.14B), arriving at the model depicted in Figure 
3.16C. Simulations from this subsequent model were able to reproduce the experimentally 
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observed time-dependent response of TGF-β1. This model could account for the timing-based 
difference in the effect of BAPTA on NAD+-induced active and latent TGF-β1, but could not 
recapitulate the attenuated response seen at high dose at the early time-points (Figure 3.15A,D). 
To explain this phenomenon, we hypothesized a threshold-dependent inhibitory effect of Ca2+ on 
TGF-β1 mRNA, which was included in our final model (Figure 3.16D), described by the following 
equations:  
 
 
 
 
 
 
 
Parameter values for this model were estimated manually and are presented in Table I. An initial 
simulation was carried out with no NAD+ input, and the resulting values were used as the initial 
conditions for each of the subsequent simulations with varying concentrations of NAD+ input. This 
procedure allows the system to equilibrate to a steady state before making any perturbations, and 
corresponds to the culture of RAW 264.7 cells to allow for adherence (Figure 3.17). 
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Table 3.2 Description of parameter values used for the ODE model. 
Parameter Value Description 
k1 30/hr Rate of NAD+ consumption to form cADPR 
k2 10/hr Rate of formation of X2 
k3 1/hr Rate of formation of TGF-β 1 mRNA from X2 
kNd 1/hr Degradation rate of NAD+ 
kCd 1000/hr Degradation rate of Ca2+ 
kTld 56/hr Degradation rate of Latent TGF-β1  
kTad 12/hr Degradation rate of Active TGF-β1 
kXd 1.3/hr Degradation rate of X1 and X2 
kTmd 3.9/hr Degradation rate of TGF-β1 mRNA 
kact 1500/Mhr Rate of activation of TGF-β1 
kTln 15/hr  Rate of translation of TGF-β1 mRNA 
kX 10/hr Rate of formation of X1 
kneg 4.5/Mhr Rate of Ca2+ -mediated degradation of TGF-β1 mRNA 
βC 12/hr Basal rate of Ca2+ production in cell 
βm 2/hr Basal rate of TGF-β1 mRNA production in cell 
α 1 Hill coefficient for X1 production 
Cthresh 1000 Threshold for activation of Ca2+ mediated inhibition 
 
 
Figure 3.17 Full time courses for simulations of ODE model. 
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  The ODE model simulations were generally in good concordance with experimental data 
for both active TGF-β1 (Figure 3.15C vs. 3.15A) and latent TGF-β1 (Figure 3.15F vs. 3.15D), 
although we observed a discrepancy at early time-points (1 and 2 h) for latent TGF-β1 (Figure 
3.15 F vs.D).  
We next attempted to validate the predictions of both the statistical and ODE models 
experimentally, at both the protein and mRNA levels. We first subjected RAW 264.7 cells to 10, 
100, or 1000 µM NAD+ for 16 h, a time point not used for the calibration of either model. As seen 
in Figure 3.18A-B, the statistical model was able to accurately predict the levels of active and 
latent TGF-β1. The ODE model was able to recapitulate the increase in active and latent TGF-β1 
induced by 10 and 100 µM NAD+, respectively, but was unable to capture the attenuated response 
to the 1000 µM NAD+ dose observed at 16 h. 
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 Figure 3.18 Validation of computational models of the effects of NAD+ on active and latent TGF-β1. 
The predictive capacity of the statistical model created with the data in Fig. 3.13 was tested by treating RAW 264.7 
cells with 0, 10, 100, or 1000 µM NAD+ for 16 h (a time point not used in the construction of the model). The cultures 
were stained for the presence of active (Panel A) or latent (Panel B) TGF-β1. Open bars show actual data (Panel A: 
n=6, *P<0.05 vs. 0, 10 and 1000 µM NAD+, **P<0.05 vs. 0 and 10 µM NAD+; Panel B: n=6, *P<0.05 vs. 0, 10 and 
1000 µM NAD+, **P<0.05 vs. 0 and 10 µM NAD+; #P<0.05 vs. 0 µM NAD+). In both panels, gray bars show 
predictions using a statistical model and black bars show predictions using an ODE model as described in the Materials 
and Methods. Panel C: Total RNA was isolated from untreated (control) or RAW 264.7 cells treated with 10, 100, or 
1000 µM NAD+ for 21 h followed by Northern blotting and analysis for TGF-β1 mRNA as described in the Materials 
and Methods. The relative amount of mRNA is presented as the ratio of mRNA to 18S RNA  
 
3.2.3.7 NAD+ increases the expression of TGF-β1 mRNA in a manner predicted in silico  
We next examined the effects of NAD+ on TGF-β1 mRNA. TGF-β1 can auto-induce its own 
mRNA expression (125), and this auto-induction is presumably driven by exposure of cells to 
active TGF-β1. Since extracellular NAD+ led to the activation of latent TGF-β1 protein and the 
increased expression of latent (total) TGF-β1 protein, we hypothesized that exposure to NAD+ 
would lead to increased TGF-β1 mRNA as well. Moreover, since the maximal activation of TGF-
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β1 by NAD+ occurred at 1 h, whereas maximal NAD+-stimulated latent TGF-β1 expression was 
seen at 6 h but persisted to 24 h, we examined the effects of NAD+ on TGF-β1 mRNA at 21 h. As 
seen in Figure 3.18C, increased expression of TGF-β1 mRNA was observed with as little as 10 
µM NAD+, and persisted at levels of NAD+ up to 1000 µM. As described in Figure 3.16B (see 
above), a mathematical model that invoked only the auto-induction of TGF-β1 was incapable of 
replicating the persistence of elevated TGF-β1 mRNA and protein at later time-points observed 
experimentally. In contrast, a mathematical model that included a hypothetical, Ca2+-independent 
pathway acting at the level of TGF-β1 mRNA induction (Figure 3.16D) accurately predicted the 
experimental data on NAD+-mediated TGF-β1 mRNA induction (Figure 3.18C). 
3.2.4 Discussion 
A large and growing class of DAMPs has emerged in over the past decade as pro-inflammatory 
endogenous cellular products that stimulate inflammation (e.g. the production of TNF-α when 
released in settings of cell stress or cell death) (121). Canonical DAMP’s include high mobility 
group box-1 (HMGB1), S100A, uric acid, and heat shock protein-70 (HSP-70) (121). However, 
relatively little attention has been paid to endogenous anti-inflammatory compounds derived from 
cells, mediators that include adenosine (138), ubiquitin (139), and hemopexin (140). Herein, we 
have identified and partially characterized a novel pathway of TGF-β1 regulation by extracellular 
NAD+ in mouse macrophage-like cells, using combined biochemical and in silico methods (Figure 
3.19), and our results suggest that NAD+ may be another member of this emerging group of anti-
inflammatory DAMP’s. 
 100 
 Figure 3.19 Mechanisms by which NAD+ modulates TGF-β1.  
Exposure to extracellular NAD+ increases both the expression and activation of TGF-β1. NAD+ signals through 
cADPR and Ca2+ to activate TGF-β1, which can then auto-induce its own mRNA production, leading to increased 
expression of latent TGF-β1 protein. The effect of NAD+ depends on the prior conversion to cADPR, an effect 
antagonized by the cADPR antagonist 8-Br-cADPR. The effects of NAD+ and cADPR require Ca2+ mobilization, are 
mimicked by Ca2+ agonists (Bradykinin, Ionomycin) and are inhibited by Ca2+ antagonists (BAPTA, Verapamil). 
Mechanistic mathematical modeling of the complex effects of NAD+/cADPR/Ca2+ on TGF-β1 suggests a Ca2+-
independent pathway for NAD+ signaling, as well as a slow mechanism for inhibition of TGF-β1 activation that is 
induced at high levels of Ca2+. 
 
Indeed, an emerging literature raises the possibility that NAD+ could be released by 
parenchymal cells in the setting of cellular stress or injury (122), and to exert various effects on 
inflammation. Granulocytes treated with NAD+ exhibited increased production of reactive oxygen 
species and other features consistent with activation (141). There is also extensive evidence that 
T-cell signaling is affected by NAD+, with ultimate effects on proliferation and apoptosis (142-
148). Furthermore, several studies have shown that NAD+ can protect against inflammatory stress 
both in vitro and in vivo (149, 150), in part via reduced activity of the central inflammatory 
transcription factor NF-κB (manuscript in preparation). We have also found that treatment of 
endotoxemic mice with NAD+ could protect from lethality in the case of mice injected with high 
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dose LPS, and greatly reduced plasma TNF-α and NO2-/NO3- and elevated IL-10, in mice 
subjected to low-dose LPS (manuscript in preparation). 
Based on these data, we hypothesized that NAD+, like other DAMPs, would have to act 
on nearby macrophages to induce classical anti-inflammatory cytokines. Given the long-
recognized, potent, and generally localized effects of TGF-β1 in inflammatory settings (124), we 
hypothesized that one mechanism by which NAD+ could exert such potent effects would be via 
modulation of this cytokine. 
The canonical signaling intermediary that controls the extracellular functions of NAD+ 
appears to be cADPR, which has been reported to lead to the release of Ca2+ from ryanodine-
sensitive intracellular stores (122). In most models of extracellular signal transduction, NAD+ is 
converted to cADPR and nicotinamide by extracellular ADP-ribosyl cyclase (122). The cADPR 
then enters cells through either a CD38-dependent (151) or –independent (152) mechanisms. The 
resulting increase in intracellular cADPR concentration leads to binding of cADPR to ryanodine-
sensitive calcium channels on endoplasmic reticulum (ER) membranes. This binding increases the 
probability that the channel will be in an open conformation, allowing the release of ER calcium 
stores to the cytoplasm (122). 
While a role for extracellular cADPR in intracellular signaling events has been reported, 
there are other mechanisms through which extracellular NAD+ may act on cells. It has been 
proposed that extracellular NAD+ may modulate cellular responses by acting as a substrate for 
endogenous ADP-ribosyltransferases (ARTs) (153, 154). Five mammalian ARTs (ART1–5) have 
been identified (155). Interestingly, CD38 has also been shown to possess ADP-ribosyl transferase 
activity (156). The ARTs are structurally and functionally related to cholera and pertussis toxins, 
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which interfere with signal transduction in human host cells by ADP-ribosylating regulatory G-
proteins (122). Several structurally unrelated inhibitors of ART were found to inhibit LPS-induced 
production of reactive oxygen intermediates and TNF-α by human mononuclear cells (157, 158). 
Our results demonstrate that mouse macrophage-like cells treated with NAD+ exhibit 
elevated expression of both active and latent TGF-β1, with a biphasic time course that also depends 
on the specific concentration of NAD+. In an attempt to discern the mechanisms responsible for 
this complexity, we utilized both data-driven and mechanistic computational modeling. Complex, 
multidimensional features of inflammation and associated processes (e.g. apoptosis) have been 
elucidated using such computational methods, for example suggesting that the regulation of the 
transcription factor NF-κB involves oscillations in the expression of its inhibitor, IκB (159) and 
that signaling for apoptosis can be reduced to two principal components (51). An initial statistical 
analysis suggested that the interactions among NAD+, latent TGF-β1, and active TGF-β1 were 
non-linear. A series of non-linear mechanistic mathematical models of increasing complexity were 
generated in an attempt to determine the mechanisms responsible for these non-linear interactions. 
When combined with our biochemical data, our models suggested that NAD+ mediates its 
complex effects on TGF-β1 via cADPR, secondary to stimulation of Ca2+ fluxes. Our results do 
not rule out a role of ARTs in the effect of NAD+ on TGF-β1, however. In fact, the inability of 
our mechanistic mathematical model–which does not incorporate the ARTs- to fully predict the 
multiphasic behavior of TGF-β1 in response to NAD+ may suggest that we have not fully 
accounted for all the relevant biological mechanisms in modeling this process. 
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In our studies, we found that blocking Ca2+ with the Ca2+ chelator BAPTA inhibited the 
activation of TGF-β1 by NAD+ or cADPR, and that treatment with the Ca2+agonists ionomycin 
and bradykinin both induced increased expression as well as activation of TGF-β1. These studies 
suggest that modulation of Ca2+ is a central mechanism responsible for the elevation of TGF-β1. 
However, in multiple attempts, we could not reproducibly demonstrate Ca2+ fluxes in RAW 264.7 
cells (data not shown). Interestingly, while many cell lines exhibit Ca2+ fluxes in response to 
extracellular NAD+ (160, 161), there are no published reports of ryanodine-sensitive Ca2+ flux 
measurements in RAW 264.7 cells. It is therefore unclear if the effects of NAD+ and cADPR 
require the activation of ryanodine-sensitive Ca2+ channels. Moreover, our data suggest that the 
effects of NAD+ on TGF-β1 requires L-type Ca2+ channels, though we have not defined the 
specific channels involved. 
There are several limitations to our study. The first is that, though the main finding of 
NAD+/cADPR-induced induction of TGF-β1 was shown both in RAW264.7 cells and in primary 
macrophages, the detailed time- and dose-curve experiments were carried out only in the former. 
We note that the extensive time- and dose-curve studies performed over many repeats would have 
been extremely cumbersome in primary cells. Moreover, we expect to have observed much greater 
variability in the biological responses studied. Another limitation is the extensive use of semi-
quantitative immunocytochemistry for these studies. Indeed, the expression of latent and active 
TGF-β1 can be assessed by various methods, including ELISA, cell-based bioactivity assays, 
Western blotting, and immunocytochemistry to detect cell-associated TGF-β1 (162). In our prior 
work establishing the utility of this assay (134), however, we showed the concordance between 
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this method and other methods of determining TGF-β1. Furthermore, prior studies had shown that 
TGF-β1 is predominantly cell-associated (132, 133, 163, 164). 
In conclusion, our results thus point to NAD+ as one of a growing group of agents 
(proteases, plasmin, chaotropic agents, acid pH, radiation, and oxygen and nitrogen free radicals) 
(126) capable of activating TGF-β1, and have at least partially elucidated the novel biochemical 
pathway by which these effects on TGF-β1 occur. Our studies may further suggest that one 
mechanism by which anti-inflammatory DAMPs exert their actions is via activation of TGF-β1. 
Moreover, our studies highlight the utility of traditional biochemical/pharmacological studies 
coupled with computational modeling in defining novel biological mechanisms. 
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4.0  CONCLUSIONS 
The overarching goal of this dissertation was to understand how a complex inflammatory 
response arises from the coordination of several inflammatory mediators. This involves 
quantitative measurements at a systemic level, data-driven modeling to extract meaningful 
mechanistic features of the response, and subsequent development of mechanistic models for 
simulation and analysis. The latter part is especially useful for connecting the results of high 
throughput data analysis back to the underlying functional biology as it relates to system behavior. 
The innate immune response is fascinatingly robust to a wide range of conditions, yet surprisingly 
susceptible to breakdown in diseases of acute inflammation. By following a comprehensive 
systems biology approach as outlined in Section 1.2, we hypothesized the identity of these control 
points and gained insights into directing their modulation for therapy.  
The inflammatory response to biological stress is generally beneficial, but can lead to 
disease when over-exuberant or inadequate. The complex and often dual role of inflammation in 
health and disease has presented a major challenge to developing effective therapeutics and 
diagnostics. In this dissertation, we tackled this complexity by studying the interplay of molecular 
mediators of the acute inflammatory response. These mediators serve as a communication medium 
to coordinate the innate immune response among various cell types, but their functional roles often 
change depending on context and timing (8, 165). To address this complexity, we analyzed the 
concentrations of numerous inflammatory mediators across time using a flexible generalization of 
Dynamic Bayesian Networks. By allowing parameters of interactions to vary, this approach 
ensured that we captured interactions that may be nonlinear or inconsistent across time and 
therefore missed using standard approaches. In the setting of pediatric acute liver failure (PALF), 
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we identified key differences in the networks of patients that were survivors versus non-survivors 
when other analyses proved inconclusive. This work also showed that inflammatory networks can 
be used both as biomarkers and to generate mechanistic hypotheses for the progression of 
inflammation in PALF, a poorly understood disease. Similarly, we identified key mediators and 
differences in the inflammatory networks in trauma patients as well as a mouse model of trauma 
and hemorrhage. By comparing results from other in vitro, in vivo, and clinical settings, we 
identified a conserved network motif of cross-regulating chemokines that appears to broadly 
orchestrate the acute inflammatory response.  
We were particularly interested in further studying the early regulation of inflammation in 
trauma. Therefore, to elaborate on the directed but abstracted chemokine network identified by 
DBN, we developed a logical model of these interactions calibrated to reproduce the averaged data 
of trauma patients with different injury severities. By comparing the dynamics resulting from 
different starting conditions, we showed that the clinically observed heterogeneity in individual 
inflammatory responses is a function of particular initial conditions. Interestingly, we were also 
able to show that heterogeneity in the time for simulations to reach steady state mapped well onto 
differences in patient discharge times of moderately vs. severely injured patients. The ability of 
this mechanistic model to capture both inflammatory trajectory and clinical outcome differences 
suggests that the hypothesized interactions represent an important point of control regulating the 
progression of acute inflammation.  
Finally, we studied a particular pathway of interest in depth, namely the activation of TGF- 
β1 by NAD+. Our work showed that the unusually complex dose and time-dependent response of 
TGF-β1 activation by NAD+ could not be explained by a linear signal flow. We developed a 
differential equation model, and performed iterative experiments and model refinement to partially 
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identify the signaling pathway that leads to the observed complex response. This work established 
a model-guided mechanistic understanding for the previously unexplained anti-inflammatory 
effects of NAD+. 
The keystone of this work has been the ability to investigate both the topology and function 
of acute inflammatory circuits by connecting experiments with data-driven and mechanistic 
systems modeling. The next steps will involve iteration of targeted experiments to disrupt the 
chemokine network at varying points along the pathway, much like in our NAD+ study, except 
extended across a multiplexed signal response measurement.  
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APPENDIX A 
SUPPLEMENTARY INFORMATION FOR SECTION 2.3 
 
Figure A1.1 
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 Figure A1.2 
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 Figure A1.3 
 
 
A.1 DETAILS OF PATIENT-SPECIFIC PRINCIPAL COMPONENT ANALYSIS 
The goal of this analysis was to identify subsets of mediators that were most strongly correlated 
with the inflammatory response trajectory of a given PALF patient.  To accomplish this, we 
utilized PCA to determine the dominance of each mediator relative to all other measured mediators 
that accounted for a given patient’s inflammatory response during the seven days from which the 
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serum samples were taken.  A minimum of 3 samples were available for cytokine analysis for each 
patient during the seven days following enrollment into the PALFSG.  First, serum sample 
underwent cytokine measurements that were then normalized so that all cytokine levels were 
converted into the same range (from 0 to 1). Next, PCA was computed utilizing the normalized 
cytokine results derived from all samples that were collected for each patient. A PCA score was 
calculated for each cytokine, summarizing the relative degree to which that cytokine contributed 
to the inflammatory response for that patient over time.  This was calculated by scaling each 
principal component’s eigenvector by its respective eigenvalue and summing together the 
coefficients (loadings) that correspond to a given cytokine over all eigenvectors (sufficient to 
capture at least 95% of the variance in the data).  These PCA scores taken together made up a 
patient’s “inflammation barcode.” This barcode was used to group patients using hierarchical 
clustering as described below. Resultant patient sub-groups were then cross-correlated with 
clinical outcomes: spontaneous survivor, non-survivor with native liver, or received liver 
transplant.  
A.2 DETAILS OF HIERARCHICAL CLUSTERING ANALYSIS 
The goal of this analysis was to highlight the natural variability, as well as any overlap, in 
inflammatory mediators from PALF patients that survived spontaneously without LTx, that died 
without receiving LTx, or that received LTx. Hierarchical clustering is a simple and unbiased 
method for segregating series of numerical values by similarity to each other. The limitation of 
this analysis is that the cluster must be built pairwise; since it is purely based on the similarity 
between the data, and the cluster may lack biological relevance(1). This analysis was performed 
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for all the inflammatory analytes – both unprocessed and following the patient-specific PCA 
described above – as published previously(2). Each row of the data matrix corresponds to either a 
single sample from patient (in raw data clustering) or a single patient’s “inflammation barcode” 
derived from PCA clustering (see above), and each column corresponds to anti-inflammatory 
analyte (26 total: 25 cytokines/chemokines along with NO2-/NO3-). The magnitudes of these values 
were log-transformed and indicated by colors. The dendrogram (a branching diagram used to show 
relationships between members of a group) on the y-axis shows the similarities among samples 
according to their correlation measures (the correlation between the inflammatory mediators 
profiles) across all analyte values. The calculation is performed by using the Bioinformatics 
Toolbox in Matlab® 7.6.0, and the code for this algorithm has been made available publicly (2). 
 
Luminex technology affords us the advantage of making many cytokine measurements 
from the same biological sample. Our dataset consists of 215 serum samples, each yielding 26 
mediator measurements. We consider each set of mediator measurements belonging to the same 
serum sample to be a single point in 26-dimensional cytokine space. We used the Euclidean 
distance between these points in 26-dimensional space as the distance metric in our hierarchical 
clustering scheme. When clustering these raw data, we took each of the 215 points to be 
independent, even though several of them came from the same patient (median = 4 samples/ 
patient). Because each serum sample was independent, there was no guarantee that all samples 
from a given patient would cluster together. This led to the possibility that two measurements from 
the same patient could be assigned to different clusters. We examined the two clusters resulting 
from the first separation in the dendrogram,  and found that samples from the same patient were 
rarely segregated into opposite clusters, For 32 out of 49 total patients, all serum samples clustered 
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together. Of the 17 remaining, there were only 4 patients whose data points were split equally 
between the two clusters. Of the 13 patients whose data were segregated unequally, only two 
patients had more than one data point in their minority cluster. Relabeling those points as each 
patient’s majority cluster did not lead to a significantly different clustering (adjusted rand index 
was 0.59, where perfect agreement yields rand index = 1, no agreement = 0(3)).  The resultant 
clusters also showed no strong correlation with clinical outcomes (adjusted rand index was 0.023). 
From this analysis, we concluded that unsupervised clustering of raw cytokine measurements was 
incapable of predicting clinical outcomes for these patients. 
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APPENDIX B 
B.1 RULES FOR BOOLEAN MODEL 
 
nodeX* =     ISS  
IP10_hi* = IP10  
IP10* =  nodeX and not (MCP1 and MIG) 
MCP1* = ISS_hi or (MCP1 and not IP10_hi)  
MCP1_hi* = ISS_hi and MCP1 and not IP10_hi 
MIG* = ISS and MIG and not IP10_hi and not MCP1 
IL6* = MIG or MCP1 
IL6_hi* = MCP1 and not IP10_hi 
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